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1ABSTRACT
This dissertation explores the importance of mass transfer, equilibrium, and
recognition elements on performance of immunoassay platforms. Atomic Force
Microscopy (AFM) and Surface-Enhanced Raman Scattering (SERS) are employed as
readout methods. AFM was utilized to evaluate the effectiveness of monoclonal
antibodies used in a heterogeneous immunoassay for porcine parvovirus (PPV) and feline
calicivirus (FCV). These results were employed to develop immunoassay protocols for
PPV and FCV, and to assess the effect of elevated temperatures on the rate of mass
transfer, and therefore the accumulation of PPV and FCV. Theoretical accumulation rates
were compared to experimental observations as monitored by AFM. The effect of sample
volume and capture area on limits of detection was examined for PPV utilizing SERS as
a readout method. A model of the equilibrium for heterogeneous immunoassays revealed
that the use of small capture substrate areas and large sample volumes would prevent
depletion of the analyte solution, and would provide the highest surface concentration of
analyte. Experimental findings for the detection of PPV upheld this prediction. Finally,
the use of aptamers as alternatives to antibodies in a SERS-based detection platform for
thrombin was examined. The conditions for aptamer immobilization and thrombin
extraction were evaluated, the limit of detection for the aptamer-based assay was
compared to that for an antibody-based assay, and possible underpinnings for the
differences in performance discussed.
2GENERAL INTRODUCTION
Dissertation Organization
Heterogeneous immunoassays have been used for several years for detection of
bioanalytes. Throughout this time improvements in sensitivity, selectivity, speed and
specificity have continued to be critical focal points. This dissertation seeks to further
advance these performance merits through investigation of two readout methodologies:
atomic force microscopy (AFM) and surface enhanced Raman scattering (SERS).
This dissertation is organized into six sections. The first section gives a review of
current methods for immunoassay detection highlighting the potential benefits of using
AFM and SERS as readout methodologies. Approaches to improve the speed of these
assays are briefly discussed along with a description of a new class of molecules known
as aptamers. Aptamers are emerging as possible alternatives for antibodies as the
selective recognition elements in a wide range of assays.
Four original research chapters follow the Introduction, each presented as a
separate manuscript that will soon be submitted for publication. Chapter 1 discusses the
optimization required for designing an immunoassay protocol utilizing AFM as a readout
technique. This Chapter describes a method for detection of feline calicivirus (FCV) and
porcine parvovirus (PPV) using AFM and this protocol is used for Chapters 2 and 3.
Chapter 1 also demonstrates the importance of screening antibodies to identify those
which give the best sensitivity. Chapter 2 extends the method developed in Chapter 1 by
studying the effect of elevated temperature on the sensitivity and speed of the assay.
Chapter 2 shows that elevated temperatures dramatically reduce incubation times with
3only marginal loss in sensitivity. Chapters 3 and 4 employ SERS as a readout technique.
Chapter 3 explores the benefits and drawbacks of decreasing the area of the capture
substrate and increasing the sample volume as a means to achieve the highest possible
surface concentration of analyte, allowing for improvements in detection limits. Chapter
4 investigates the use of aptamers as replacements for antibodies in a detection scheme
for thrombin. The conditions for this assay were optimized and the results were compared
to an assay employing antibodies. The dissertation concludes with a general summary
and a discussion of the future directions building on this work.
Literature Review
Traditional Immunoassays
The term immunoassay refers to a measurement that employs antibodies as
analytical reagents. The first immunoassays (radioimmunoassay) were developed in the
1960s for insulin and thyroxine.1 At the time the importance of this type of analysis was
underestimated by the scientific community. Since then, the specificity, stability and
versatility of antibodies have been exploited to produce analytical methodologies for a
wide range of targets. Today, immunoassays play a leading role in areas of human and
veterinary medicine as a tool for early disease diagnosis and post-treatment monitoring.2
Immunoassay technology has been applied to many other fields of research including
food safety3, 4 and environmental analysis.5-7 Recent trends in the field of immunoassay
research focus on development of multiplexed systems, real-time monitoring, automation,
4and more specific reagents and labels (aptamers).8, 9 In nearly all cases, approaches to
further advances in speed, sensitivity, and specificity continue to be vital research areas.
Immunoassays rely upon the molecular recognition characteristics of antibodies.
Antibodies are proteins in the immunoglobulin class that have binding sites specific for
target antigens. The recognition between antibodies and antigens results from a
combination of electrostatic, hydrophobic, hydrogen and Van der Waals interactions.
Typical equilibrium constants between antibodies and antigens range from 107 to 1012 M-
1
.
9 One advantage of using antibodies as analytical reagents is that many can be produced
from hybridoma cell lines that can be continuously cultured to produce the antibody;
therefore there are no limits to the amount of antibody that can be produced10. Other
advantages are that the antigen used in identification of the antibody does not have to be
in a purified form10, and antibodies impart high selectivity and affinity to the
methodology. Limitations of antibodies include the use of animals for production, which
limits targets to those that are well tolerated in animals (i.e. toxins cannot be used). The
identification and production of antibodies is labor intensive and expensive, and
antibodies are prone to batch to batch variability. Finally, antibodies are sensitive to
temperature, require physiological conditions, and undergo irreversible denaturation10.
These limitations have inspired the study of aptamers as replacements for antibodies in
biosensing applications, and aptamers are the topic of Chapter 4 of this dissertation.
Immunoassays can be categorized into two methods: competitive and non-
competitive. Non-competitive assays (sandwich type) are the focus of this dissertation
and will therefore be the subject of this review. Noncompetitive immunoassays require
5the binding of two antibodies to the antigen, one being labeled to provide the analytical
signal (Figure 1).
Solid Substrate
Immobilized capture antibody
Target
Tracer Antibody
Figure 1. Solid-phase immunoassay in a non-competitive format.
In general, a solid phase is prepared with an excess of purified antibody specific
to the target analyte. Many different solid phases have been explored for antibody
immobilization, including plastic microtiter plates, polymer beads, and membranes.9
Immobilization procedures for the antibody vary for each solid phase and include simple
adsorption (through hydrophobic or hydrophilic interactions) and covalent tethering.
When passively adsorbed, antibodies undergo conformational changes which decrease
their activity up to 90%.9 In the presence of other proteins, the antibodies may exchange
with the excess proteins to the solid substrate reducing coverage by up to 15% in a 16 h
period.9 Nevertheless, passive adsorption continues to be used because of its ease of use
and, even with the loss of antibody activity, assays performed in this manner still provide
adequate limits of detections and dynamic ranges. Covalent immobilization requires the
use of a liking agent such as glutaraldehyde9 and provides a more rugged capture
6substrate. However, these procedures can be complicated and add several steps to the
overall procedure, sometimes without any tangible benefit.
The resulting solid phase, generally referred to as a capture substrate, is then
blocked to reduce non-specific binding of the analyte and labeled antibody to the solid
phase, and to coat non-specific epitopes of the immobilized antibody. The selection of a
blocking agent must be optimized for each application. Blocking agents are typically
proteins or nonionic detergents and include bovine serum albumin (BSA), casein, dilute
skim milk, Tween, and Triton. Commercial blocking agents such as Superblock and
Blotto are also available, which are unspecified mixtures of skim milk proteins, anti-
foaming agents and nonionic detergents.9 Small proteins are used for blocking since their
small size has a greater probability to fill in the gaps left between the much larger
antibodies which make up the capture substrate. Optimization of the blocking agent is
crucial because some blockers may increase non-specific binding. Moreover, some assays
may not require a blocking step. The mechanisms by which blocking agents reduce non-
specific adsorption is not well understood, and blocking agents have been shown to
interfere with specific as well as non-specific binding.9
Once the capture substrate is prepared, the target is exposed to the substrate and
allowed to bind for a specific amount of time (incubation time). The time required for the
solid phase immunoassay to reach equilibrium can be very long, and methods to improve
diffusion of targets to the capture substrate are the focus of Chapter 2. Another key aspect
of target extraction is the specificity of the interaction between the capture antibody and
the analyte. The specificity of this interaction has a large impact on the sensitivity (i.e.
7limit of detection) of the assay. This concept has been examined in Chapters 1 and 4 of
this dissertation.
Finally, the captured analyte is labeled with excess of tracer antibody, and washed
to remove extra tracer antibodies. This tracer antibody provides a signal that is directly
proportional to the analyte concentration. The use of two different antibodies for the
noncompetitive immunoassay often imparts greater specificity because cross-reacting
species rarely bind both the capture and the tracer antibodies.
Detection limits for noncompetitive immunoassays are controlled by the affinity
of the involved antibodies, experimental error, non-specific binding, and the strength of
the signal from the tracer antibody. In this immunoassay format, the analytical signal is
directly proportional to the amount of analyte present; thus low concentrations of analyte
produce low signals. Therefore, to drive the limits of detection to lower levels, brighter
labels are needed. Importantly, the analytical signal obtained from analyte binding must
be distinguishable from that of non-specific binding.
The type of label used for the tracer antibody varies, and conventional
immunoassay labels include radioactive isotopes, enzymes, and fluorophores. The next
section will briefly examine each of these techniques, followed by the fundamental
underpinnings of two alternative readout methodologies (AFM and SERS). The
discussion will also detail their strengths and weaknesses.
Radioactive isotopes provided the analytical signal for the very first
immunoassay, relying on the disintegration (“decay”) of the radioactive isotope for
quantification. With this approach, the unstable radioisotope is covalently attached to the
tracer antibody, and the radiation can be of two types:  particles, or  rays. The preferred
8type is  rays due to their greater emission and simpler instrumentation requirements.
Radioactive isotopes have the distinct advantage of not being susceptible to
environmental factors such as pH or ionic strength. Additionally, most biological
matrices have very low radioactive backgrounds, contributing to their high sensitivity.
Unfortunately, radioactive labels emit radiation over a broad energy range, providing a
challenge for multiplexing due to overlapping spectra,11 and the health hazards associated
with radiation exposure have discouraged their use.12
Introduced in the 1970s,13 enzymes are the most widely used label in
immunoassays9, the most typical format being an enzyme-linked immunosorbant assay
(ELISA). For ELISA, an enzyme is conjugated to the tracer antibody, and as a final step
in the assay, a substrate is added to the reaction vessel. The product of the enzyme-
substrate reaction is monitored. Quantification of the reaction can be achieved with visual
assessment, fluorescence, luminescence, and electrochemistry methods.9 ELISA
application offers high sensitivity due to the inherent amplification that results from the
enzyme-substrate reaction. The challenges with enzyme labels are related to the diffusion
limitation of immunoassays. Enzymes are large biomolecules with small diffusion
coefficients, requiring long sample incubation times for the enzyme to reach the capture
substrate. In addition, enzymes have similar properties as antibodies and therefore are
prone to non-specific binding resulting in high background signals that limit sensitivity.
Enzymes are also susceptible to environmental factors such as pH, temperature, and ionic
strength, all which may alter the activity of the enzyme. Finally, multiplexing with
enzyme labels is difficult because the products often have spectra that overlap.
9Today, fluorescent labels are commonly used in immunoassays due to their
improved sensitivity over absorbance measurements9. Unlike radioactive isotopic labels,
fluorophores are sensitive to their local environment and produce high background
signals from scattering and fluorescence of the sample or substrate. These limitations
have been overcome by the use of time-resolved fluorescence measurements and labels
with long-lived fluorescence14. The emission spectrum from many fluorophores is broad,
presenting a challenge in multiplexing. However, spatial separation of multiple antibodies
on the solid phase allows for the use of a single label in a multiplexed format (i.e. the
location identifies the antigen, and the intensity determines concentration).
Alternative Readout Techniques
Atomic Force Microscopy (AFM)
In Chapters 1 and 2 of this dissertation, atomic force microscopy (AFM) has been
explored as an alternative readout method for immunoassays due to its ability to
distinguish nanometrically sized objects based upon morphology. Because of the ability
of AFM to interrogate molecular level interactions at solid phase interfaces, it has been
exploited as a tool to study many biological phenomena. AFM has also been used to
image bacteria,15 viruses,16 and proteins.17 AFM has also been applied as a detection
method for viruses, offering a distinct advantage in that it can be carried out in a fluid
environment that allows biological entities to be in their natural state.16 AFM procedures
also do not require sample preparation steps that can alter the structural properties of
biological reagents.17 The ability of AFM to probe into adsorption of proteins at the solid-
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liquid interface provides information that is central to a range of bio-technologies
including biosensors, biomaterials, and biomedical applications.17
First reports of AFM as a tool for analysis of immunosensing platforms were
performed by our laboratory several years ago.18 This study used compositionally
patterned surfaces and determined that controlling orientation of antibodies to the solid
phase increased epitope density.18 Another application used substrates with micrometer-
sized regions of rabbit IgG covalently bound and separated by a hydrophobic
octadecanethiolate monolayer. AFM was used to monitor the height changes upon
antigen binding, and real-time analysis revealed that the antigen was bound in ~5 min.19
Other immunoassays utilizing AFM include detecting antigen-antibody binding through
the use of colloidal gold-labeled antibodies to measure an increase in surface
roughness.20, 21 Researchers have also used AFM as a tool for immunosensing based upon
height changes in a protein pattern. In a slightly different venue, AFM has been employed
as a tool to fabricate protein patterns.22, 23 These techniques have been extended to
imaging of protein patterns, created with different protein immobilization procedures, to
determine orientation of the proteins.22, 23 AFM has also been used to study the viability
of immobilized proteins on a microtiter plate, finding that only 5% of passively adsorbed
antibodies were active.24
One application of AFM as a tool for biochemical analysis involves measurement
of ligand-receptor binding forces. Molecular interactions between ligand binding pairs is
of critical importance in determining biological function as it pertains to structural
features.17, 25 To interrogate these interactions, one of the binding pairs is typically
immobilized on a tip and the other bound to a surface.26-28 Adhesion (binding force) is
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measured by conducting a pull-off experiment.29 These experiments are sometimes
difficult to interpret due to non-specific interactions from improper orientation of one of
the ligands.29, 30 The first reports on using AFM to probe ligand binding interactions
involved the use of the well studied biotin-streptavidin system.31-33 These experiments
require immobilization strategies that allow spatial separation of ligands or receptors to
ensure a response due to specific binding. In addition, these determinations require a
statistically valid number of force curves to gain useful information about the
interactions.
A more basic and direct use of AFM to study antibody-antigen binding is by
topographical imaging. Advantages of AFM as a readout method in this manner are its
ability to directly image/quantify the target. In many cases, a secondary labeling step is
not required. Height changes of 3-4 nm have been observed for adsorption of anti-IgG to
a surface and the same changes are observed when antigen is bound.19
AFM has also been used as a tool to image and detect viruses.16, 34 High resolution
images of viruses that have been immobilized on a variety of surfaces have been obtained
with AFM, providing insight into the dimensions of virus particles and the architecture of
their surfaces.16 These images show the potential of AFM to differentiate viruses based
upon their sizes and shapes, and viruses with diameters ranging from 17-150 nm have
been examined.16 At present, however, this technique lacks the sensitivity required for
diagnosis in that the limit of detection for this platform in only 108 pfu/mL.35
The ability of AFM to measure individual biological events has allowed it to
become a key instrument for biological analysis. Since AFM can image large areas and
has the sensitivity to detect single antibody-antigen pairs, it can interrogate many
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addresses in a single scan, providing a high throughput readout method.19 However, the
slow analysis speed limits this application. Advances in development of a high-speed
AFM have allowed it to meet these needs,36-40 including techniques to increase the scan
speeds of contact and intermittent contact imaging41, as well as a fast driving technique.42
These developments, coupled with the imaging capabilities of AFM will continue to
place AFM as an invaluable tool in analysis of biological interactions.
Surface-Enhanced Raman Scattering (SERS)
SERS has been employed as a readout technique for immunoassay because of
several advantageous characteristics43-53 and is the technique utilized in Chapters 3 and 4
of this dissertation. The first advantage is that, in contrast to normal Raman spectroscopy,
SERS signals rival those of fluorescence. Raman bands, however, unlike those of
fluorescence, are narrow, reducing spectral overlap and facilitating multiplexed detection
with several Raman reporter molecules in one address. Another advantage of SERS is
that optimum excitation wavelengths are dictated by the underlying enhancing substrate
rather than the Raman reporter molecule, allowing only a single excitation wavelength to
excite several labels. Finally, Raman scattering is unaffected by its environment,
producing a stable and reproducible signal.
The earliest work in adapting SERS to immunoassay readout involved detection
of thyroid stimulating hormone using antibodies bound to a roughened silver substrate.53
The built in amplification of enzymes was adapted for SERS readout by choosing a
product from the enzyme reaction that is Raman active.46 The Raman active product was
then adsorbed onto colloidal silver for SERS readout. Label free assays for SERS have
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also been developed in which a biomarker for bacterial spores (calcium dipicolinate) that
exhibits intrinsic Raman scattering was bound to a roughened silver substrate.49
Work in our laboratory has focused on the use of extrinsic Raman labels (ERLs)
for SERS detection in a solid-phase sandwich immunoassay format.43, 44 ERLs are
designed to contain the immuno-recognition element as well as the Raman active
molecule. The gold colloid then serves as the enhancing surface, and the ERLs are used
as the tracer antibody in the sandwich format. The design has been implemented in the
multiplexed detection of IgG protein45 and has been shown to have femtomolar level
sensitivity for prostate specific antigen, a biomarker for prostate cancer.44 Finally, the use
of ERLs has been applied to large bioanalytes through detection of feline calicivirus.43
Overcoming the Diffusion Limit
As mentioned above, a challenge in many immunoassay formats is the time
required for analyte and label (tracer antibody) to diffuse to the solid substrate. The ideal
kinetics for a bimolecular reaction occur in solution; constraining one analyte to a solid
support imposes a strong effect of diffusion constraints.54 Long incubation times are
required for an equilibrium to be reached when one reactant is immobilized, as is the case
in solid phase immunoassays.9 Though only marginally investigated, ways to overcome
the diffusion could offer significant improvements to the efficiency and possibly the
sensitivity of immunoassays. Since antibody-antigen reactions are considered to be
“instantaneous” (i.e., mass transfer limited), the rate limiting step of immunoassays is
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diffusion to the substrate55-59 as many biological molecules have small diffusion
coefficients. The diffusion coefficient is described by:
D = kT/6r (1)
where k is Boltzmann’s constant, T is temperature, r is the radius of the analyte and  is
viscosity. Since r falls in the denominator, large values for r (i.e., large biomolecules) will
decrease the diffusion coefficient, slowing diffusion rates.
Diffusion control of solid phase immunoassays has been supported by
experimental evidence as well as theoretical models that describe solid phase
immunoassay kinetics.56, 57 Recent theoretical treatments argue that the time required for
picomolar or better detection limits is unacceptably long when diffusion alone is used to
transport large analytes to a solid phase.60 This analysis suggests that limits of detection
are restricted by the diffusional transport and not signal transduction. The opportunity,
therefore, is found in increasing flux of analyte to the surface to take full advantage of the
recent breakthroughs in readout methodology that allow quantification at ultra-low levels.
It has been estimated that by applying stirring to protein microarrays, the speed of the
reaction could be improved by 40-fold.54
Only a limited number of methods have been proposed for increasing mass
transport of analytes and labels to the solid phase to exploit the instantaneous recognition
rates of antibody-antigen interactions. One method involves electric-field driven assays in
which analytes are driven to locations based upon their inherent charges. Two different
strategies have been proposed. The first involves driving analytes electrophoretically
through solution to spots on a microelectrode array.61, 62 Another method manipulates
analytes electroosmotically in microchannels.63 These methods allow incubation times to
15
be reduced dramatically (1 min with electroosmotic transport) but suffer in that each
analyte has a unique charge, and therefore different experimental conditions are required
for each immunoassay.
A technique that can be more universally applied to overcoming mass transport
has been developed in our laboratory and is based upon the electrochemical theory of
rotated disk electrodes.64 This concept was first applied in an immunoassay to increase
flux of redox probes generated by an enzyme label for a sandwich immunoassay with
amperometric detection. In our laboratory it was further exploited to drive the transport of
analytes to the solid phase platform with a rotating disk. Porcine parvovirus was chosen
as a model because of its small diffusion coefficients, and atomic force microscopy
(AFM) was used as a readout method. The use of rotation reduced incubation times and
resulted in an improved limit of detection over an assay preformed under diffusion
controlled conditions. Rotation was also applied to a full sandwich immunoassay,
providing increase in flux for both the analyte and the label, utilizing SERS as a readout
method. This assay led to a reduction in incubation time from 24 h to 25 min with a
tenfold improvement in the limit of detection.64
Elevated temperature has also been explored as a means to decrease incubation
times and is the subject of Chapter 2 in this dissertation. An increase in temperature
speeds up incubation times by 1) increasing the diffusion coefficient, 2) increasing the
association constant between antibodies and antigens,65 and 3) inducing convection
through a thermal gradient. As shown in equation 1, an increase in temperature will
increase the diffusion coefficient. Simultaneously, an increase in temperature decreases
viscosity, which further improves the diffusion coefficient, offering a simple means for
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decreasing incubation times. Finally, when assay samples are exposed to a heating
element, the changes in temperature between the solid phase support and the solution
may not occur at the same rate, causing a thermal gradient in the sample. The thermal
gradient then induces convection, which delivers analyte to the substrate more quickly.
Aptamers
Aptamers are single stranded oligonucleotides (40-100 bases) thought to rival if
not surpass antibodies as molecular recognition elements in selectivity, specificity and
affinity.10 Discovered in 1990 independently in the labs of Joyce,66 Szostak,67 and Gold,68
through a process termed Systematic Evolution of Ligands by Exponential Enrichment
(SELEX), aptamers can be developed for a variety of targets ranging in size from small
organic molecules to proteins. Recent reviews summarize existing aptamers and their
targets.69-73 The development of aptamers has changed the way single stranded
nucleotides are viewed. Traditionally looked upon as linear molecules that contain
information (tapes), single stranded oligonucleotides are now described as globular
molecules.74 Since their invention, aptamers have been extensively studied and
demonstrate great potential as a tool in molecular biology, diagnostics, molecular
medicine, and drug discovery.72 Aptamers have been isolated that bind tightly and
specifically to targets for uses in sensor technology. Aptamers have also been found that
inhibit proteins biological function, positioning them as potential therapeutic reagents.75
The molecular discrimination that aptamers exhibit has been shown to be up to 10 times
more efficient76 than that of antibodies and can even discriminate between enantiomers.77
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The SELEX process used to develop aptamers that bind selectively to targets
involves the isolation of a nucleic acid sequence from a starting pool of ~1015 sequences.
The molecular diversity contained in this large pool contributes to the success of finding
a unique sequence that interacts specifically with the target, and the degree of this
diversity supersedes that of other screening libraries.10 Once isolated, these single
stranded oligonucleotides exhibit complex molecular recognition properties based upon
their three-dimensional conformation.
Random library of
oligonucleotides
Target
Incubate library
with target
Separate bound
DNA from
unbound DNA
Remove
bound DNA
from target
Amplify selected
DNA by polymerase
chain reaction (PCR)
Repeat
Figure 2. The SELEX process.
The SELEX process is shown in Figure 2. The isolation process of aptamers
begins with a starting pool of single stranded oligonucleotides synthesized with random
sequences flanked by primer sequences on either end for easy amplification during the
selection process. The sequences are then exposed to a target molecule in the conditions
of choice (i.e. buffer composition, temperature, etc)10 and allowed to bind. Typically, the
target is immobilized on a support to facilitate removal of sequences that do not bind the
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target.71 The weakly bound sequences are removed by washing or eluting them from the
solid support. Sequences that strongly bind the target must then be eluted off the target,
typically by using methods that denature the 3-D structure of the oligonucleotides (i.e.
heat or basic pH). Once the sequences that bind strongly to the target have been eluted,
they are amplified through the polymerase chain reaction (PCR). PCR is a technique that
amplifies oligonucleotides through a series of heating and cooling steps with the use of an
enzyme (typically Taq polymerase), primers (complimentary to the primer sequences
flanking the random sequence of the initial pool), and deoxynucleotide triphosphates
(dNTPs). This amplification procedure increases the concentration of the sequences that
exhibit binding to the target. These sequences are then exposed to the target again and the
process is repeated several times, allowing for competitive binding between the
sequences until the oligonucleotides with the desired binding affinity have been selected.
The number of rounds required for identification depends upon the stringency of each
round and on the nature of the target. Typically enrichment is reached in 8-15 cycles.10
Once the starting pool has been reduced to a few highly binding oligonucleotides, the
sequences are determined.
Once an aptamer is selected and sequenced, its 3-D structure is determined by
methods such as NMR, X-ray crystallography, and circular dichroism (CD). The highly
selective binding of aptamers to their targets is attributed to specific interactions (i.e.
hydrogen bonds, electrostatic interactions and stacking)78 between the target and the
phosphate groups of the oligonucleotides backbone and the bases.73 The 3-D structure of
the aptamer (sequence specific) provides the scaffold for binding of the target. Many 3-D
structures of single stranded oligonucleotides have been characterized, including stem-
19
loop bulge, psuedoknot, hairpin, and G-quartet. In order to form these structures, the
minimal sequence required is usually 15-50 bases; therefore, the random region of the
starting pool for SELEX must be at least 15 bases.69
Limitations on the applicability of aptamers as analytical reagents include their
susceptibility to nuclease attack. However, the concerns of stability are more important
for aptamers used in vivo (therapeutics) than for aptamers used in sensor applications.69
DNA can be stored for long periods of time without degradation in a laboratory setting,
unlike antibodies which typically lose activity after long periods of storage.
Aptamers offer several advantages as alternatives for antibodies in biosensing
applications. Once isolated, aptamers are more easily manufactured than antibodies, as
they are produced synthetically by automated methods instead of involving animals and
in vivo conditions. The synthetic production of aptamers allows them to be produced with
extreme accuracy and reproducibility, unlike antibodies that are prone to batch to batch
variations.10 In addition, the synthetic production of aptamers allows them to be
manipulated easily (i.e. attach enzymes or dyes) without changing the activity of the
aptamer. The conformation stability and small nature of aptamers allows an increase in
surface coverage and reduction of steric hindrance, possibly improving biosensor
sensitivity. Also, the attachment of oligonucleotides to surfaces has been demonstrated to
be very reproducible.10 Aptamer conformation can be regenerated after denaturation
through control of buffer and ion compositions, unlike antibodies whose activity cannot
be restored after denaturation. Finally, aptamers can be generated for a greater number of
targets than antibodies including toxic and non-immunogenic analytes,10 and can be
20
selected in a wide range of conditions including non-physiological buffers and
temperatures.10
Biosensors are only as good as the selectivity and affinity of the molecular
recognition element they rely upon.10, 71, 79 Since aptamers offer similar characteristics as
antibodies but are more readily manufactured, they are well-poised to serve as
replacements for biosensing applications, including therapeutics and diagnostics.10 Many
of the same traditional readout methods for immunoassays using antibodies have been
explored using aptamers including radio isotopic,80 fluorescence,81-84 and enzyme85-88
labeling. Other methods for detection include quartz crystal microbalance (QCM),79, 89
and molecular beacons.90, 91 Electrochemical detection has become a popular method for
assays with aptamers because of the high sensitivity, fast response and low cost of
electrochemical methods.92-96 Typical electrochemical detection systems require labeling
of the recognition moiety with an electrochemically active species. Aptamers can be
more readily labeled with such species than antibodies, without loss of activity. An
aptamer-based electrochemical sensor for platelet-derived growth factor has recently
been shown to have picomolar sensitivity in complex clinical samples.97
Two-site binding assays (sandwich immunoassays) have been developed using
aptamers as both recognition moieties and combining antibodies and aptamers for
recognition.10 Fluorescence detection using aptamers has been studied extensively and
found to be highly sensitive and selective.81-83 Aptamers have been used in a variety of
biosensing platforms and have recently been extended to sensor arrays for the detection
of proteins, proving to be superior over protein arrays by their ability to be regenerated
multiple times.98, 99 Fluorescence detection in an array format using aptamers has been
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shown to simultaneously detect three cancer-associated proteins.100 Aptamers have the
potential to dramatically change sensor development by providing detection systems with
tailor designed characteristics that can be applied to unlimited analytes in a variety of
matrixes.101
One consideration when applying aptamers to biosensing platforms is that the
optimal conditions for using the aptamer must be delineated for every assay. Unlike
antibodies, aptamers do not have a universal set of conditions (physiological) for optimal
performance.88 For instance, the binding buffer composition must be optimized to include
the appropriate ionic strength83 as well as temperature and immobilization procedures.87
Ionic strength typically has a large effect on aptamer performance, and therefore
additions of cations such as Mg2+ and K+ must be examined. Each aptamer possesses a
unique set of condition requirements to provide the most sensitive assay performance.87
Dissertation Overview
Based on the themes discussed above, this dissertation explores ways to improve
upon immunoassay methods using AFM and SERS as readout techniques. Each of the
following chapters is presented as an individual manuscript that describes the research
efforts in improving immunoassay protocols, including antibody screening, assay time
reduction, sample concentration, and aptamers as alternative reagents. Chapter 1 begins
with describing the optimization of a universal protocol for virus detection with AFM
readout, and use of this protocol to screen for the most sensitive antibodies for the
detection method. Chapter 2 extends this concept by exploring elevated temperatures as a
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means to decrease incubation times. Small substrates and large sample volumes are
employed in Chapter 3, along with SERS, to achieve attomolar detection limits of PPV.
Aptamers are explored in Chapter 4 as replacements for antibodies using SERS as a
readout method. The dissertation is concluded with a summary of the research presented
and a discussion of the future directions of the work.
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ABSTRACT
The ultrahigh resolution imaging capabilities of atomic force microscopy (AFM)
is explored as a readout method for the detection of viruses and as a tool to screen the
performance of monoclonal antibodies (mAbs) for solid-phase immunoassays. This paper
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demonstrates that AFM is a potentially powerful readout method for viral pathogens,
using feline calicivirus (FCV) and porcine parvovirus (PPV) as test systems. The viruses
are captured directly via specific mAbs and quantified in a label free assay via AFM. The
effectiveness of the platform was evaluated through assessment of cross-reactivity and
non-specific binding. The results show that the capture substrate is specific for the virus
of interest, and blocking of the solid-phase is not necessary for FCV detection. After
specificity was established, mAbs for each virus were screened, and limits of detection
were determined. Dose-response curves using the most effective antibodies are linear
with a detection limit of 3.2 x 106 TCID50/mL for FCV and 6.4 x 104 TCID50/mL for
PPV. Finally, insights into the effect of sample volume and solution depletion were made
from preliminary data.
INTRODUCTION
Medical and veterinary hospitals demand rapid, sensitive, and specific diagnosis
techniques to detect a wide range of bacterial and viral pathogens.1 The methods
available today for virus detection and quantification (e.g., immunosorbent electron
microscopy,2, 3 ELISA,4, 5 PCR,6-11 tissue culture infective dose (TCID50),12 fluorescent
immunoassay,13, 14 high frequency nanoelectromechanical devices15 and serological
testing14), however, tend to lack the speed and sensitivity necessary to mount a rapid
response in the event of an outbreak. As a potential means to address this need, we have
developed a label free, specific, and reproducible methodology for the detection of viral
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pathogens utilizing the nanometric imaging capabilities of atomic force microscopy
(AFM).
AFM, as an ultra high resolution imaging tool, not only can be used to enumerate
biological objects16 like viruses, but also can be used to distinguish differences based on
size and shape. Immunoassays utilizing AFM for readout have been performed
previously for the detection of immunoglobulin G molecules17, 18 and for the detection of
the capsid proteins of viruses.19 Although previous reports have shown that AFM can be
used to image whole viruses,20, 21 there are few reports of immunoassays that make use of
AFM to detect and quantitate whole viruses from complex solutions.22 We therefore seek
to exploit AFM as a readout method by drawing on its potential versatility for the label-
free, size/shape-based detection of whole virues. We suggest that size-based
discrimination may: (1) be beneficial by providing a means to minimize sample
complications from non-specific adsorption and (2) simplify procedures by elimination of
a labeling step.
The solid-phase assay platform herein employs an antibody-modified substrate to
selectively capture viruses, which are then imaged and enumerated by AFM. Feline
calicivirus (FCV) and porcine parvovirus (PPV) are employed to test the merits of AFM
as a virus detection method. Both viruses are non-enveloped and have well defined
spherical structures (diameter of 36 nm for FCV and 25 nm for PPV).23 By establishing
procedures for the detection of these model systems, we speculate that the protocol will
be readily translatable to viruses with shared morphological similarities such as human
caliciviruses, noroviruses, and saporviruses.24
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The proposed method utilizes monoclonal antibodies (mAbs) that are covalently
immobilized on a nanometrically smooth gold substrate via a thiolate adlayer, which is
formed from a coupling agent, dithiobis(succinimidyl propionate) (DSP), as shown in
Scheme 1. After mAb immobilization, the capture substrate is exposed to the virus
solution. This step selectively extracts viruses from the sample solution. Finally, the
substrates are rinsed, dried, and imaged with AFM. The simplicity of the assay platform
allows for fast, accurate analysis of mAb specificity and sensitivity.
In order to further evaluate the capabilities of this strategy, AFM was used as a
tool to study non-specific interactions as well as the effectiveness of antigen-antibody
interactions in solid-phase immunoassays. To assess non-specific binding, bovine serum
albumin (BSA) was employed as a blocking agent, a competitive assay was performed,
and the cross-reactivity of the capture substrate was analyzed. Several antibodies for FCV
and PPV were screened to evaluate the performance of the antibodies in a heterogeneous
assay platform.
Methods for antibody screening include enzyme-linked immunoadsorbent assay
(EIA),25-27 kinetic exclusion fluorescence immunoassay (KinExA),28 fluorescence
photobleaching,29 and immunoprecipitation of radiolabeled antigen.30 Some of these
methods chemically modify the mAb or antigen (e.g., radioimmunoassay and fluorescent
immunoassays) which may affect the antibody-antigen interaction. Other methods require
a secondary labeling step to measure the free antibody (e.g., EIA, and KinExA). AFM
offers advantages over these methods by not requiring modification of either the antibody
or antigen and providing a direct measure of the antibody-antigen complex. Affinity of
the mAbs may be influenced by the assay conditions used,27 and the straightforwardness
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of the AFM detection platform allows assay conditions to be changed to reflect the
antibody affinity under a variety of conditions.31
EXPERIMENTAL
Reagents. FCV (titer 5.0 x 108 TCID50/mL) and PPV (titer 3.2 x 109 TCID50/mL,
4.48 x 1012 PPV/mL32) were obtained from National Animal Disease Center (NADC).
Monoclonal antibodies (mAbs) were supplied by NADC, purified with a protein G
column (Bio-Rad) and were stored in 10 mM phosphate buffered saline (PBS). FCV
mAbs are designated 2D10-1C4, 3B12-1C8, and 4G1-2F4, while mAbs for PPV have the
identifiers #3, #8, and #9. DSP, PBS packs, BSA and octadecanethiol (ODT) were
obtained from Sigma-Aldrich. Poly(dimethylsiloxane) (PDMS) Dow Corning Sulgard
184 was from Ellsworth Adhesives. Contrad 70, used for cleaning glass, was provided by
Decon Labs, and two-part epoxy (EpoTek 377) used for making template stripped gold
(TSG), was from Epoxy Technology. Borate buffer packs were from Pierce, and all
buffers were passed through a 0.22-µm syringe filter (Costar) before use.
Preparation of TSG. Capture substrates were prepared using TSG. TSG has a
roughness factor of 0.6 nm, which provides a sufficiently smooth “background” for the
size/shape identification of FCV and PPV by AFM. The TSG was constructed by
resistively evaporating 250 nm of gold (purity 99.9%) onto a clean p-type silicon wafer
(University Wafer 4” (111)) using an Edwards 306A resistive metal evaporator at a
deposition rate of 0.1 nm/s. Microscope slides were cut into 1 x 1 cm glass chips and then
were sequentially cleaned ultrasonically in dilute surfactant solution (Contrad 70),
deionized water, and ethanol for 30 min each. Epoxy was applied to the clean glass chips,
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and the chip was placed epoxy-side down on the gold coated silicon wafer, and cured at
150 ˚C for 105 min. The glass chips were gently removed from the silicon wafer, leaving
a flat layer of gold on top of the glass chips.
Capture Substrate Preparation. The 1 x 1 cm TSG pieces were immediately
used to create an antibody-coated capture substrate. First, PDMS was cast over a
fluorine-terminated p-type silicon wafer and cut into a 1 x 2 cm piece with a 3-mm
circular well in the center. The PDMS stamp was soaked in a 1-mM ethanolic ODT
solution for 1 min, dried with high-purity nitrogen, and then placed on the TSG pieces for
~ 30 s. This step creates a hydrophobic monolayer of ODT on the gold substrate with a
bare gold spot33-35 that confines small volumes of aqueous samples to a small area,
minimizing material consumption. Substrates were rinsed with ethanol, dried with a
stream of high purity nitrogen, and soaked in a 0.1 mM ethanolic solution of DSP for ~12
h. This procedure forms a 3-mm diameter adlayer of a succinimide ester terminated
monolayer that can be used to covalently bind antibodies via an amide linkage.17, 36-38
After adlayer preparation, the samples are rinsed with ethanol and dried under a stream of
high purity nitrogen.
Anti-FCV and anti-PPV mAbs were covalently immobilized through coupling to
the terminal succinimidyl ester of the DSP-derived monolayer17, 37, 38 by applying 20 µL
of the protein solution (100 µg/mL in 50 mM borate buffer (pH 8.5)) onto the substrate
and reacting for ~8 h at room temperature in a humidity chamber. The surface
concentration of each mAb is assumed to be the same because each antibody was purified
to 99.9% with a protein G column before immobilization to the capture substrate.
Afterwards, the substrates were rinsed three times with 2.5 mL 10 mM PBS (pH 7.4),
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followed by addition of 20 µL of the virus solution and incubation for ~16 h in a
humidity chamber. FCV was diluted in cell culture media, while PPV was diluted in 10
mM PBS. Finally, the substrates were rinsed three times with 2.5 mL of 10 mM PBS (pH
7.4), and once with a 3-s stream of deionized water to remove salt residue. Residue
removal facilitated AFM enumeration. Finally, substrates were dried with a stream of
high purity nitrogen.
For the blocking studies, the capture substrate was exposed to varying
concentrations of BSA, diluted in 10 mM PBS, for ~16 h. BSA solutions were rinsed
from the capture substrates three times with 2.5 mL of 10 mM PBS. Specificity studies
were performed using anti-San Miguel sea-lion virus mAb (anti-SMSV) and anti-bovine
viral diarrhea mAb (anti-BVD), mAbs that do not selectively bind to FCV or PPV.4, 5, 23,
39 Competitive assays were performed using a 50-µL solution of FCV, inoculated with
differing concentrations of anti-FCV mAb in 10 mM PBS for 8 h. The inoculated FCV
solution was then exposed to the anti-FCV capture substrate for ~8 h.
Dose-response curves were constructed and repeated at least twice for each
experiment. Error bars represent the standard deviation of the average number of viruses
bound in 25 µm2 from five different images on each sample.
Instrumentation. The substrates were characterized by collecting 5 x 5 µm AFM
images with a MultiMode NanoScope IIIa SFM (Digital Instruments) equipped with a
150-µm scanner. Images were obtained under ambient conditions in TappingMode at a
rate of 1.5 Hz, and the topography was recorded for further analysis. The setpoint
oscillation amplitude was set to 80% of the free oscillation amplitude. Images were
collected with n(+)-silicon TESP cantilever/tips (Nanosensors) with a length of 118 nm, a
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width of 27-29 nm, thickness of 3.6-4.5 nm, a spring constant of 32-70 N/m, and a
resonant frequency of 327-421 kHz. The number of viruses bound in each image was
counted manually using a pen style colony counter (Sigma).
RESULTS AND DISCUSSION
FCV was used to establish the most favorable assay conditions and to determine
the specificity of the immunoassay format with AFM readout. Three tests were
performed to evaluate the specificity of the assay, and the optimized conditions were used
to identify the most effective monoclonal antibodies for FCV and PPV detection.
Detailed calibration curves were employed to delineate limits of detection and potential
methods for improving performance were examined.
Tests for Specificity
Test I. Effect of BSA Blocking. Several studies were performed to determine if
non-specific binding of the capsid proteins on the FCV to the un-reacted succinimidyl
groups of the DSP-derived monolayer would prove problematic. These tests employed
BSA, a small protein that is ~10 times smaller than FCV. BSA is often used as a blocking
agent in immunoassays to “fill in” parts of the solid phase that are not covered by the
immobilized antibody, thereby reducing non-specific binding.36
Figure 1 shows AFM images of capture substrates blocked with different
percentages of BSA for ~16 h and then exposed for ~8 h to a 5.0 x 108 TCID50/mL
solution of FCV. The FCV appear as spherical objects with an average height of ~22 nm
(Figure 1). The size of the viruses is somewhat smaller than expected (36 nm) because of
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dehydration. Irregularly shaped objects are also evident in the images, and are attributed
to cell debris and other components of the diluting media. We add that the viruses appear
to have varying sizes in the x-y (surface) plane. This observation is attributed to tip
convolution effects, which reflect the subtle differences in the size and shape of the tip
asperity.40, 41 These results, importantly, demonstrate the ability of AFM to distinguish
objects based upon their height, regardless of tip convolution effects.
The images in Figure 1 illustrate that there is little difference in the number of
captured FCV when different percentages of BSA are used for blocking. The results have
been summarized in Figure 2. The amount of captured FCV was not affected by BSA
blocking at each concentration of FCV (5.0 x 107, 2.5 x 108, and 5.0 x 108 TCID50/mL)
tested. The addition of BSA does not appear to have an impact on the assay, as samples
prepared without BSA treatment have approximately the same surface concentration as
those modified by exposure to BSA, as seen in Figure 2. These results lead us to believe
that non-specific interactions between FCV and any un-reacted groups at the terminus of
the DSP-derived monolayer are minimal.
We suspect that this finding is a result of the complex matrix of the freeze/thaw
lysate used for FCV dilution. The lystate contains many small proteins and other
additives that could be acting as blocking agents, much like BSA, when the FCV is
exposed to the capture substrate. The exposures to FCV solutions without BSA blocking
support this claim. We conclude from these results that blocking of the solid-phase is not
required for FCV detection with AFM.
Test II. Competitive Assay. In order to further ensure that FCV binding to the
capture substrate is due to specific mAb interactions, a competitive assay was performed
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in which a standard solution of FCV was mixed with varying amounts of anti-FCV mAbs
before exposure to the capture substrate. The ability of FCV to bind to the capture
substrate should, therefore, progressively diminish as the number of epitopes on FCV
available for binding decreases. The amount of anti-FCV mAb needed to fully coat all of
the FCV epitopes was estimated as 4.5 x 1012 mAbs, given 50 µL of an FCV
concentration of 5.0 x 109 TCID50/mL and 180 epitopes per FCV. Since the concentration
of FCV is given in units of TCID50/mL and not virus particles/mL, the number of
molecules of anti-FCV mAb inoculated with FCV was varied from 1.0 x 1014 to 2.0 x
1010.
The results of the competitive assay are presented in Figure 3. As anti-FCV mAb
is added to the FCV solution, the number of captured FCV undergoes a dramatic
reduction between 5 x 1011 and 1 x 1012 molecules of anti-FCV. At the highest
concentration of anti-FCV mAb only an average of 11 viruses were bound in a 25-µm2
area. At the lowest concentration of anti-FCV mAb, on average 375 viruses were bound
in the same area. These results confirm that FCV is binding to the capture substrate
through specific interactions between the epitopes on the FCV and the surface bound
mAb.
These results also allow an estimation of the FCV concentration in number of
virus particles/mL. Since the concentration of mAb required to fully coat all the FCV in
the 50 µL sample can be determined from Figure 3, we can then calculate how many
FCV particles are in the sample. At a concentration of 1.0 x 1012 mAbs, most of the FCV
have been coated, giving rise to an FCV concentration of 1.1 x 1011 particles/mL. This
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calculated concentration is 20 times larger than the TCID50/mL value, meaning that every
TCID50 unit is the equivalent of ~20 virus particles.
Test III. Antibody Specificity. Lastly, the specificity (i.e., cross-reactivity) of the
capture substrate was evaluated by constructing capture substrates with antibodies not
produced for FCV. Figure 4 shows images of anti-SMSV mAb and anti-BVD capture
substrates exposed to 5.0 x 108 TCID50/mL of FCV. The anti-SMSV mAb is specific for
a part of the capsid protein unique to SMSV but is not specific for an antigenic site
common to the calicivirus family.4, 5, 23 Anti-BVD mAb is specific for viruses that are
unrelated to FCV.36, 39 As seen in Figure 4, few FCV bind to either surface, showing that
neither capture substrate takes up FCV, and confirming that the capture substrates are
specific for FCV.
Dose-Response Curves and Limits of detection (LODs)
Dose-Response Curves. For each virus, several mAbs were screened for
effectiveness. Three different mAbs for FCV and PPV, immobilized on capture
substrates, were tested by developing separate dose-response curves. As found earlier, the
viruses appear in Figure 5 as spherical objects with average heights of ~22 nm for FCV
and ~17 nm for PPV. Figure 5A was collected using anti-FCV mAb 2D10-1C4 and a
FCV concentration of 2.5 x 108 TCID50/mL. Figure 5B utilized anti-PPV mAb #9 and a
PPV concentration of 1.6 x 107 TCID50/mL.
Dose-response curves, based on the AFM images, for each antibody are shown in
Figure 6. The slopes of the dose-response curves are related to the binding affinities of
the mAbs, and therefore can be used to identify the most effective antibody for this
detection platform. Test solutions for FCV spanned from 2.5 x 108 to
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5.0 x 106 TCID50/mL and were diluted in freeze/thaw lysate media for FCV. PPV
dilutions were carried out in 10 mM PBS and ranged from 1.6 x 107 to
3.2 x 105 TCID50/mL. Figure 6 demonstrates that the most sensitive and effective anti-
FCV mAb is 2D10-1C4, and the least sensitive is 4G1-2F4. While the differences in
sensitivity are not nearly as pronounced for PPV as for FCV, the most sensitive mAb for
PPV is anti-PPV mAb #9.
The differences in the dose-response curves for the different antibodies can be due
to many factors, including a conformational change to the mAb when immobilized,
which may cause a loss in activity.30 Additionally, each mAb binds to different epitopes
of the viruses, and these antigenic sites may be altered or blocked when immobilized,
which would also result in a change of activity.36 Some mAbs may undergo these
changes more than others, and AFM offers a unique method to test the activity of
individual immobilized Abs.
From the dose-response curves in Figure 6, limits of detection (LODs) for each
mAb were determined. The LOD is defined as the concentration of virus that can be
determined above the average blank signal plus three times the standard deviation of the
blank samples. The blank signals are attributed to particles in solution that have a similar
size and shape as the viruses, and also from contamination of the transfer pipettes. These
data translate to a LOD of 3.2 x 106 TCID50/mL for anti-FCV mAb 2D10-1C4, which is
competitive with other methods of virus detection (e.g., 105 viruses/mL for fluorescence13
and 108 viruses/mL for AFM detection22). For anti-FCV mAb 3B12-C8 the LOD is
6.9 x 106 TCID50/mL and for anti-FCV mAb 4G1-2F4, the LOD is determined to be
3.2 x 107 TCID50/mL, which follow intuitively from the dose-response curves. A LOD
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for PPV is calculated for mAb #9 to be 6.4 x 104 TCID50/mL and 6.5 x 104 TCID50/mL
for mAb #3. The mAbs #8 for PPV has a LOD of 8.6 x 104 TCID50/mL. These results
establish the performance of the mAbs and demonstrate the usefulness of AFM as a
screening tool.
Given the calculated conversion of TCID50/mL for FCV of 20, the LOD achieved
for FCV is 6.4 x 107 virus particles/mL. The conversion factor for PPV from TCID50/mL
to virus particles is 1400 (derived by fitting experimental curves of PPV accumulation
with respect to rotation rate),32 yielding a LOD of 9.0 x 107 virus particles/mL. Readout
by AFM is not the limiting factor in determining these LODs. In theory, AFM is able to
detect a single binding event; the challenge arises from finding that single binding event
on the relatively large capture area. Also, the capture of small numbers of viruses in large
volumes is time consuming unless steps are taken to increase the rate of transport to the
surface. Additionally, the use of small volumes may cause depletion of the virus
concentration in solution, which further slows diffusion and limits the number of viruses
that can be extracted. These issues are being investigated in depth by our research team.
Improvement of LODs. As a preliminary investigation into improving limits of
detection, larger volumes of FCV were exposed to the same 3-mm diameter capture
substrate. Figure 7 shows AFM images of four different volumes exposed to the 3 mm
substrate for ~16 h. The results clearly show that the exposure volume has a large effect
on the number of viruses that bind. Figure 8 summarizes the findings from Figure 7, and
demonstrates that the number of viruses bound increases with sample volume and then
levels off at about 40 µL. We speculate that increases in sample volume and/or decreases
in substrate area may provide a simple means of improving LODs. These data suggest
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that by using a 40-µL sample volume the LOD could be improved by at least a factor of 2
over a 20-µL sample volume. Further investigations into this observation are currently
being studied.
CONCLUSIONS
AFM has been shown as a valid readout method for detection of viral pathogens
based on the size and shape of the virus. The LOD for FCV was shown to be 3.2 x 106
TCID50/mL with a dynamic range of 2.5 x 106 to 2.5 x 108 TCID50/mL. The LOD for
PPV was found to be 6.4 x 104 with a dynamic range of 6.4 x 104 to 1.6 x 107
TCID50/mL. The technique was also shown to be a sensitive method for antibody
screening for mAbs used in solid phase immunoassays. The specificity of the method was
fully investigated, and it was shown that a blocking step is not required for AFM readout
with FCV. The utility of AFM as a readout method to investigate the factors that affect
immunoassay performance, including mAb effectiveness and blocking reagents, has been
demonstrated. Additionally, we have shown a method for estimating virus concentration
in virus particles/mL based upon known mAb concentrations virus epitopes.
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Scheme 1
(A) Immobilize antibody on substrate via DSP
(B) Expose substrate to sample, capturing FCV or PPV
(C) Collect AFM images of FCV or PPV bound to capture substrate
DSP Adlayer
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Figure 1. AFM micrographs (5 x 5 µm) of capture substrates blocked for ~16 h with
different concentrations of BSA. The images represent the surface bound FCV after
exposure to a 5.0 x 108 TCID50/mL solution after blocking with 0% (A), 1% (B), 3% (C),
5% (D) BSA, and (E) topographic line scan of FCV showing an average height of ~22
nm.
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Figure 2. Bar graph showing the effect of different amounts of BSA used for blocking
the capture substrate on three different concentrations of FCV.
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Figure 3. Competitive assay to test the specificity of the capture substrate. The data was
obtained by collecting AFM micrographs (5 x 5 µm) of each sample exposed to varying
amounts of anti-FCV mAb molecules prior to exposure to the capture substrate.
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Figure 4. AFM images (5 x 5 µm) of anti-SMSV mAb (A) and anti-BVD mAb (B)
capture substrates exposed to 5.0 x 108 TCID50/mL of FCV.
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Figure 5. AFM micrographs (5 x 5 µm) and topographic line scans of (A) FCV (mAb
2D10-1C4, 2.5 x 108 TCID50/mL), (B) PPV (mAb #9, 1.6 x 107 TCID50/mL), and (C)
blank samples.
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Figure 6A. Dose response curve responses for three different mAbs substrates exposed to
FCV. Limits of detection are 3.2 x 106 TCID50/mL for mAb 2D10-1C4, 6.9 x 106
TCID50/mL for mAb 3B12-1C8, and 3.2 x 107 TCID50/mL for mAb 4G1-2F4.
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Figure 6B. Dose response curve responses for three different mAbs substrates exposed to
PPV. Limits of detection are 6.4 x 104 TCID50/mL for anti-PPV #9, 6.5 x 104 TCID50/mL
for anti-PPV mAb #3, and 8.6 x 104 TCID50/mL for anti-PPV #8.
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Figure 7. AFM images (5 x 5 µm) of FCV bound to capture substrates after exposure to
(A) 5.0, (B) 10.0, (C) 20.0, and (D) 40.0 µL of a 5.0 x 108 TCID50/mL solution.
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Figure 8. Dependence of captured FCV particle density as a function of FCV volume
exposed to the capture substrate. The data were collected from AFM images (5 x 5 µm)
after the capture substrate was exposed to different volumes of a 5.0 x 108 TCID50/mL
solution.
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ABSTRACT
High throughput, sensitive, and rapid detection of viral pathogens is central to
human and animal healthcare and diagnosis. The strategy relies on how elevated
temperatures can be used to increase rates of mass transfer, potentially lowering the time
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required for sample incubation. This paper describes the development of a virus detection
method that extracts viruses at an elevated temperature to give a total sample workup
time of less than 1 h. To evaluate the use of elevated temperatures, immunoassays for
porcine parvovirus (PPV) and feline calicivirus (FCV) were studied using the direct
readout method of atomic force microscopy (AFM). PPV represents a more ideal system
in that the assays were carried out in buffered solutions. FCV, on the other hand, serves
as a more realistic model for a complex matrix (i.e., spent cell culture medium). The
accumulation rate of the viruses was examined at different temperatures. The
accumulation rate for PPV qualitatively follows theoretical predictions based on diffusion
considerations. The accumulation rate for FCV, however, exhibits a much more complex
and less tractable dependence, which is attributed to competition from components in the
sample matrix. It was determined that by increasing the temperature to 39 ˚C, an assay
carried out with 1-h incubations gave limits of detection (LODs) comparable to those at
25 ˚C for 16 h. Moreover, LODs for 1-h incubations at 39 ˚C were 10-50 times lower
than the 25 ˚C, 1 h analogs. The potential broad-based extension of this strategy is briefly
discussed.
INTRODUCTION
Solid phase immunoassays are invaluable to clinical chemistry.1 However the
never-ending demand for more rapid and sensitive tests continues to push for
enhancements in throughput, reductions in analysis time, and improvements in limits of
detection (LOD).1, 2 To these ends, recent breakthroughs, for example, in electrochemical,
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optical, magnetic, and scanning probe microscopic detection methods3-14 have driven the
LODs to femtomolar levels and lower. However, the need for long incubation times
remains problematic. This situation is due, in large part, to the small diffusion
coefficients for large-sized biolytes (e.g., antibodies, viruses, and bacteria), which yield
low rates of mass transfer to a capture substrate in quiet solutions.15 Slow rates of mass
transport can also have a negative impact on the apparent LOD because of the long times
that may be required for the system to truly equilibrate.15 In other words, the observed
LOD may be an unrecognized artifact of slow mass transport limitations rather than
signal transduction. The development of methods to increase the rate of delivery of
analytes and labels to capture substrates, therefore presents opportunities to not only
reduce incubation time, but also to improve LOD.
Examples of recent strategies that have focused on increasing mass transport
include electric fields,16-19 lateral flow assays,20-24 rotation-induced convection,25 and
temperature.26-31 Electric fields can drive analytes to specific addresses based upon the
inherent charge of the target. While dramatically reducing incubation times, this approach
must be finely tuned in order to optimally function for targets with different charges.
Lateral flow assays, in contrast, typically use a porous solid phase that has a localized
band of capture antibody positioned downstream of the sample inlet. The sample and
label move through the solid phase, concentrating the antigen upon passage through the
“capture zone.”20-24 Rotation of the capture substrate has been shown to decrease
incubation times and to improve the LODs.25
As another possible pathway to overcome mass transport limitations, this paper
investigates the use of elevated temperatures within the context of readout with atomic
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force microscopy (AFM). Elevated temperatures have been exploited to improve mass
transport for small molecules (i.e., antibodies in Enzyme-Linked ImmunoSorbent Assay
(ELISA) applications).27-31 There are few reports, however of utilizing elevated
temperatures to increase the transport of large antigens such as viruses. We add that AFM
provides a unique opportunity to explore the temperature dependence of assay
performance due to its ability to readily image nanometer-sized objects such as viruses.11,
32-34 Furthermore, AFM can function as a label-free readout method, eliminating
complications from the secondary labeling required by many other techniques.
Our approach to investigate the use of elevated temperatures to decrease
incubation times involves the capture of two different viruses, porcine parvovirus (PPV)
and feline calicivirus (FCV) to an antibody-modified gold substrate. PPV and FCV are
employed as model systems because their size (i.e., 25-nm diameter for PPV and 36-nm
diameter for FCV)35 facilitated AFM imaging and yielded small diffusion coefficients.
The gold substrate was prepared with covalently immobilized monoclonal antibodies
specific for each of the viruses. These substrates were then exposed to virus solutions for
differing times (up to 16 h) and temperatures (25 ˚C and 39 ˚C) to experimentally
monitor by AFM the rate of accumulation and potential effects on LODs. This paper,
therefore, first examines the theoretical underpinnings of how the size of an antigen and
temperature affect accumulation, and then roughly compares such predictions to our
experimental observations. Finally, the effect of incubation time and temperature on
analytical performance metrics (i.e., sensitivity and LOD) is discussed.
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THEORETICAL CONSIDERATIONS
The impact of an elevation in temperature on analyte accumulation in a
heterogeneous immunoassay is primarily an integration of three different factors. Two
factors arise from the effect of temperature on mass transfer through increases in the
diffusion coefficient,36 and in convection.37 The third results from enhancements in both
the association, ka, and dissociation, kd, reaction rate constants for the complex, which
directly translates to the equilibrium constant for the complex.26 The contribution from
the first factor, an increase in a diffusion coefficient with temperature, can be expressed
by the following equation:
D = kT/6r (1)
where k is Boltzmann’s constant, T is the absolute temperature,  is the solution
viscosity, and r is the radius of the diffusing analyte.36 As is evident, the magnitude of the
diffusion coefficient is directly proportional to temperature, and inversely proportional to
the size of the analyte. Note that the diffusion coefficient also exhibits an inverse
dependence on solution viscosity, which undergoes an increase with elevations in
temperature. Table 1 illustrates the temperature dependence of the diffusion coefficients
for spherical objects that are comparable in size to a monoclonal antibody (mAb), PPV,
and FCV at both 25 and 39 ˚C.
How these differences, albeit no more than a factor of 3.5, affect the number of
particles that in quiet solution encounter the surface of the capture substrate as a function
of time, t, can be estimated using:
 = n (Dt/2)1/2 (2)
61
where  is the surface concentration of accumulated antigens and n is the antigen particle
concentration (antigens/mL).36 The following criteria must be followed in order for
Equation 2 to be predictive: 1) each antigen that collides with the surface is
instantaneously captured; and 2) the level of accumulation is sufficiently low that the
binding of an incoming antigen is not sterically occluded by previously captured
antigens.
Based on Equation 2, Figure 1 plots  for the three different targets as a function
of time and temperature (25 and 39 ˚C) at an initial concentration of 1.0 x 1010
antigens/mL (17 pM). This concentration was chosen to parallel the conditions of the
experimental data. The accumulated antigen is well below the calculated jamming limit
for each target (175000, 13500, 30000 particles/25 µm2 for mAb, FCV, and PPV
respectively). As is seen, all accumulations increase with time (all accumulations are
greater at 39 ˚C), and the accumulation of mAbs is notably larger than either of the
viruses.
These results yield two additional insights. The first reflects how reproducibility
is intimately connected to the accurate control of incubation time. Temporal control is
much more important at short times, and with smaller antigens. This situation becomes
more readily apparent in Figure 2, which plots the derivative of the profiles in Figure 1
with respect to time. As expected, these plots show that the greatest change in
accumulation occurs at small times. The need for careful temporal control is also more
important at elevated temperatures because of the higher accumulation rates. The second
observation relates to how the rate of accumulation evolves with time and its impact on
LOD. In other words, the return in terms of improvements of LOD drops rapidly via a
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t-1/2 dependence. Thus, doubling the assay time will only improve the LOD by a factor of
~1.4.
A further perspective into this issue can be developed by examining the
accumulation at different virus concentrations, as shown in Figure 3. Assays performed at
short times and room temperature are clearly hampered because only small amounts of
antigen can be captured. For example, after 600 min at 39 ˚C, a PPV concentration of
1 x 1010 viruses/mL has resulted in the capture of 175 viruses bound in a 25 µm2 area,
while a tenfold increase in concentration to 1 x 1011 viruses/mL yields 1750 viruses in the
same area. When trying to detect ultra low levels of antigen, the amount of time required
to accumulate a detectable amount will be considerably long. Lower concentrations of
antigen require long times to diffuse to the surface, even when elevated temperatures are
used to increase the amount of captured antigen. This situation, coupled with challenges
in locating and detecting a low density of captured antigen, placing a premium on the
development of approaches to enhance mass transport.
Elevated temperatures also have an effect on the equilibrium constant, Keq, of
antibody-antigen binding, which in turn, controls the total number of analytes that can
potentially be captured. Since antibody-antigen binding is considered instantaneous,38-41
changes in Keq affect the equilibrated accumulation of antigen by changing the total
number of antigen that can be bound. The association and dissociation reaction rate of an
antibody-antigen system defines its Keq:
Keq = ka/kd (4)
where ka is the association rate constant, and kd is the dissociation rate constant. The rate
constants are known to be dependent on temperature following a Boltzman equation:37, 42
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k  exp(-Ea/kT) (5)
If both ka and kd are equally affected by a temperature change, then the value of Keq
remains fixed, and there will be no change in accumulation. If, however, one rate
constant is changed more than the other, the Keq will be different, and the level of
accumulation will be altered. In most of the studied cases, the dissociation rate of the
antibody-antigen complex undergoes a much larger change than the association rate at
increased temperatures.26 The increase in kd, and subsequent decrease in Keq, may affect
the sensitivity of the assay by limiting the total number of antigens that can be bound.
Because antibody-antigen reactions are exothermic, an increase in temperature could also
have a deleterious effect on assay performance by pushing the equilibrium to the un-
conjugated state. The extent to which this dissociation happens impedes limits of
detection by allowing fewer bound complexes at equilibrium. Therefore, the benefits of
shorter incubation times must be evaluated with respect to decreases in sensitivity.
The final contribution of temperature to antigen accumulation is through a
thermally induced convection, which increases mass transport. When capture substrates
are heated, a temperature gradient can develop in the liquid sample, causing a convective
mixing because of thermally generated density gradients. The resulting convection causes
an increase in mass transport, which often accounts for the larger than expected
accumulations that have been observed with respect to those based solely on diffusion.37,
43 The challenge, however, is that temperature gradients can be difficult to control in
multiphase systems, partially degrading reproducibility from assay-to-assay.37
Nevertheless, convection has been shown to improve the rate of accumulation by as much
as a factor of five, providing a useful method for reducing overall incubation times.37
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Thus, the improvement in analyte accumulation due to convection and the increase in
diffusion coefficients can yield reductions in incubation times without compromising
limits of detection.
EXPERIMENTAL
Reagents. FCV (titer: 5.0 x 108 TCID50/mL) and PPV (titer: 3.2 x 109
TCID50/mL) were obtained from the National Animal Disease Center (NADC). We have
recently shown that the conversion factors from TCID50/mL to the number of virus
particles/mL of PPV and FCV are ~1400 virus particles/TCID50 for PPV25 and ~20 virus
particles/TCID50 for FCV.44 The conversion factor for PPV was ascertained from fitting
experimental curves of PPV accumulation with respect to the rotation rate of the captured
substrate.25 The FCV conversion factor was determined by titrating the virus with known
concentrations of antibody and then monitoring when the binding to the capture substrate
was no longer detectable.44 We note that the later analysis relies on knowing the number
of epitopes on the virus and estimating the amount of antibody that can fully coat the
outer surface of the virus.
Monoclonal antibodies (mAbs), also provided by NADC, were purified with a
protein G column (Bio-Rad) to 99.9% and stored in 10 mM phosphate buffered saline
(PBS). Dithiobis(succinimidyl propionate) (DSP) and PBS packs were purchased from
Sigma. Octadecanethiol (ODT) was obtained from Aldrich. Poly(dimethylsiloxane)
(PDMS) was acquired from Dow Corning, and utilized to fabricate microcontact printing
stamps. Contrad 70, a mild detergent used for cleaning glass, was from Decon Labs, and
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the two-part epoxy, employed for constructing template stripped gold, was from Epoxy
Technology. Borate buffer packs were from Pierce. All buffers were passed through a
0.22-µm syringe filter (Costar) before use.
Preparation of Capture Substrate and Immunoassay Protocol. Template
stripped gold (TSG) acted as the base for preparation of capture substrates. TSG has a
low roughness factor (0.6) that facilitated the AFM-based enumeration of the two viruses,
which have hydrated diameters of ~25 nm (PPV)35 and ~36 nm (FCV).35 TSG was
constructed by evaporating 250 nm of gold (purity 99.9%) at a rate of 0.1 nm/s onto a 4-
in, p-type silicon (111) wafer (University Wafer), using an Edwards 306A resistive metal
evaporator. Microscope slides were cut into 1 x 1 cm glass chips and cleaned
ultrasonically in dilute Contrad 70, deionized water, and ethanol for 30 min each. Epoxy
cement was applied to one side of the clean glass chips, the chip was placed on the gold-
coated silicon wafer, and the wafer was cured at 150 ˚C for ~100 min. The glass chips
were then carefully detached from the silicon wafer in order to expose the underlying
smooth gold surface.
TSG was used to create antibody-coated capture substrates. First, TSG was
exposed for ~30 s to an ODT-soaked PDMS stamp with a 3.0-mm hole cut in its center.
This step creates a ring-shaped hydrophobic coating that both confines small volumes of
aqueous samples within the center of the substrate and minimizes sample and reagent
consumption. The substrates were subsequently rinsed with ethanol, dried with nitrogen,
and soaked in a 2-mM ethanolic solution of DSP for ~8 h.
The next step in the process pipetted 20 µL of either anti-FCV or anti-PPV mAbs
(100 µg/mL in 50 mM borate buffer (pH 8.5)) onto the DSP-modified domain of the
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substrate, with the covalent coupling reaction allowed to proceed for ~7 h at room
temperature. After the substrates were rinsed three times with 10 mM PBS (pH 7.4), 20
µL of room temperature virus solutions were placed on room temperature substrates,
which were then incubated either at 25 or 39 ˚C for different time intervals by placement
in a temperature equilibrated Yamato IC 400 incubator. The PPV solution was prepared
by dilution in 10 mM PBS, while FCV was diluted in spent cell culture media. Finally,
the substrates were rinsed three times with 10 mM PBS (pH 7.4), and once with a 3-s
stream of deionized water. The water rinse was necessary in order to remove salt residue,
which interfered with the enumeration of captured viruses by AFM. The substrates were
then dried with a stream of nitrogen. The steps for these immunoassay procedures reflect
earlier optimizations, which also included specificity controls to validate the use of the
two mAbs.44
Instrumentation. The substrates were characterized by collecting 25-µm2 AFM
images with a MultiMode NanoScope IIIa AFM (Digital Instruments) equipped with a
150-µm scanner. Topographic images were acquired under ambient conditions in
TappingMode using n(+)-silicon TESP cantilever/tips (Nanosensors) with a length of 118
nm, a width of 27-29 nm, thickness of 3.6-4.5 nm, a spring constant of 32-70 N/m and a
resonant frequency of 327-421 kHz. The set-point amplitude of the cantilever was set to
80% of the free oscillation amplitude, and images were collected with a scan rate of 1.5
Hz. The number of viruses bound in each image was counted manually using a pen style
colony counter (Sigma).
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RESULTS AND DISCUSSION
The goal of this work was to investigate the effect of elevated temperatures on
incubation times and analytical performance (i.e., sensitivity and LOD) for virus assays.
To achieve this goal, viruses bound to the capture substrates were enumerated with AFM,
which enables assessment of the capture step in a label-free format. AFM images and
topographical cross-sectional plots of a FCV, PPV, and blank sample (10 mM PBS) are
shown in Figure 4. The sizes of these images (25 µm2) represent interplay between image
resolution, which is a function of virus size, and scan area. As is evident in Figure 4, the
viruses appear as spherically shaped objects, while the blank sample shows no
distinguishable objects. PPV has ~17-nm height, while FCV is ~25 nm tall spheres,
while. We attribute the smaller than expected sizes to dehydration of both of the viruses.
The viruses, however, retain their general shape because of the stability of the capsid
protein coating. We add that the lateral (x-y plane) appearances of some of the viruses
vary and are somewhat asymmetrical, because of tip convolution effects.45 Importantly,
all of the captured viruses have the same average height, which allows for accurate
enumeration.
PPV Accumulation at 25 ˚C. These experiments exposed anti-PPV capture
substrates to a PPV sample (6.4 x 106 TCID50/mL, 8.9 x 109 virus particles/mL) over a
range of times. Figure 5 plots both the experimentally determined and theoretically
predicted (Equation 2) accumulation of PPV as a function of time. The curve exhibits
slightly lower accumulation than expected because the virus accumulation does not
follow the assumptions of Equation 2 (i.e., all viruses that reach the surface bind). The
experimental conditions require that the viruses reach the surface and find an available
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binding site (i.e., an antibody that is active and oriented correctly). In preparing capture
substrates, the orientation of the capture antibodies is not controlled, leaving many
inactive sites, limiting the number of binding sites available for virus capture.
Additionally, the viruses are large in size and may block active antibody sites on the
capture surface, limiting the number of virus binding sites even further (on average one
virus blocks nine antibodies). These considerations predict that the experimental
accumulation will follow Equation 3.
The curve in Figure 5 exhibits an apparent saturation at ~150 PPV bound/25 µm2,
while the predicted trend shows a continued slow increase in the accumulation. This
observation can be attributed to two factors: 1) equilibrium has been established, and/or
2) the solution has been sufficiently depleted to where the bulk concentration is changing
(i.e. the reaction has become volume dependent). If the system has reached equilibrium,
then the total number of PPV accumulated will not change, regardless of time. In the case
of depletion, the sample solution concentration is being reduced, which in turn decreases
 according to Equation 2. By calculating the total number of PPV that have been
extracted out of solution onto the capture substrate, and subtracting this number from the
initial concentration, the bulk solution concentration has been reduced by ~30%.
Additionally, after 16 h, an estimation of the diffusion layer thickness suggests that ~60%
of solution has been perturbed. These observations lead us to believe that the system has
not reached equilibrium.
PPV Accumulation at 39 ˚C. In an effort to reduce extraction times of viruses to
the capture substrate, binding curves for PPV were determined at 39 ˚C, shown in Figure
6. As seen in Figure 6, the curve levels off in ~2 h, a dramatic decrease compared to ~8 h
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at 25 ˚C. The curves for PPV at 39 ˚C follow the trend expected for accumulation
according to Equation 2. However, unlike at 25 ˚C, the accumulation at 39 ˚C is faster
than the predicted curve for 8.9 x 109 virus particles/mL, and thus does not follow
Equation 3. The predictions based on Equations 2 and 3 account for faster accumulation
due to increases in diffusion coefficients and decreases in solution viscosity, but do not
account for increases due to convection. The faster accumulation at 39 ˚C for the
experimental results as compared to the predictions is attributed to convection.
Convection has a considerable effect on the accumulation of the viruses, and control of
the convection, therefore, may provide an appealing method to reducing mass transfer
limitations.
Since we believe our systems have not reached equilibrium, it is difficult to
determine the impact of a change in K value on our systems. As with any immunoassay
protocol, a balance must be found between incubation time and sensitivity, since the
accumulation at short times (< 2 h) at 39 ˚C is less than the number of bound viruses at
room temperature for long times (> 8 h). A direct comparison of limits of detection using
different incubation times and temperatures is discussed below.
FCV Accumulation at 25 ˚C. Substrates for FCV were exposed to
5.0 x 108 TCID50/mL (1.0 x 1010 virus particles/mL) and rinsed after different incubation
times. FCV accumulation at 25 ˚C as a function of time is shown in Figure 7. In this case,
a limiting surface concentration appears to be reached in ~8 h at ~200 viruses/ 25 µm2.
Moreover, the evolution of accumulation is much different from the predicted curve for
accumulation according to Equation 3. The experimental accumulation is very slow at
short times and then increases sharply between 5 and 10 h and finally levels off.
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An important difference in the experimental conditions for FCV is the use of
spent cell culture media in the dilutions that contain many proteins and molecules not
found in PBS used for diluting PPV. These medium contain a large number of small
proteins and molecules which can potentially cover the capture substrate at a rapid rate
(see Table 1 and Figure 1). Such a coating potentially competes with antigens for surface
sites, which can slow accumulation. However, while only speculative, it appears that
once a few viruses bind, the rate of accumulation increases, suggesting that some type of
cooperative mechanism may be of importance. Nonetheless, more experiments are
necessary to realistically address this issue.
FCV Accumulation at 39 ˚C. Accumulation rates of FCV at 39 ˚C are shown in
Figure 8. Equilibrium is reached after ~2 h and is a marked improvement over those at
25 ˚C. The shape of the binding curve is similar to that observed at 25 ˚C, in that virus
accumulation is slow at first, rises quickly and then levels off.
Interestingly, the saturation points for FCV are lower at elevated temperatures
(i.e. ~200 viruses/25 µm2 at 25 ˚C and ~120 viruses/25 µm2 at 39 ˚C). We believe that
this difference, at least in part, is due to the effect of temperatures on K.
The results from these data show that in order to achieve satisfactory performance
(i.e. low detection limits) at room temperature, the viruses must be extracted for at least 8
h. The slow mass transfer of the viruses to the capture substrate illustrates how the
sensitivity of the assay is a mass transport limitation and not an artifact of the readout
methodology, emphasizing the importance of overcoming mass transfer in order to
achieve low limits of detection in short time frames. The use of elevated temperatures can
decrease the amount of time needed to extract viruses, but may have a deleterious effect
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on the achievable limit of detection. It is our speculation that the faster extraction times
are due to convection and larger diffusion coefficients, and not a change in the
association constant since it is well documented that the rate of antibody-antigen binding
is limited by mass transport rather than recognition rate.38-41
FCV and PPV Dose-Response Curves. To understand the compromise between
fast accumulation due to increased temperature and LOD, dose-response curves for FCV
and PPV were constructed at 39 ˚C for 1 h, 25 ˚C for 1 h, and 25 ˚C for 16 h. FCV was
diluted in spent cell culture media, while PPV was diluted in 10 mM PBS. Figure 9 plots
the dose-response curves for PPV, while those for FCV are presented in Figure 10. Limits
of detection were defined by the concentration yielding a signal equal to the blank signal
plus three times the standard deviation of the blank signal. From these dose-response
curves, the limit of detection for PPV is 2.1 x 105, 1.8 x 105, and 8.1 x 105 TCID50/mL for
1 h at 39 ˚C, 16 h at 25 ˚C and 1 h at 25 ˚C, respectively. The limit of detection for FCV
is 5.1 x 106, 8.1 x 105, and 4.2 x 107 TCID50/mL for 1 h at 39 ˚C, 16 h at 25 ˚C and 1 h at
25 ˚C, respectively. Upon analysis of the dose response curves, it is clear that the best
limits of detection can be achieved by long extraction times at room temperature. This
result is expected based upon the theoretical predictions and experimental evidence
shown above. Assays conducted at room temperature for only 1 h exhibit the worst limits
of detection, emphasizing the impact of mass transport on assay sensitivity. Increasing
the extraction temperature to 39 ˚C and decreasing incubation time to 1 h changes the
LOD by less than a factor of 2, as compared to 25 ˚C for 16 h. These results show that the
elevated temperatures speed up accumulation for both viruses while maintaining assay
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performance, implying that this methodology for improving mass transport may easily be
applied to solid phase immunoassays for large biological analytes.
CONCLUSIONS
Decreases in accumulation time of viruses from solution were observed when
elevated temperatures were utilized. Surface accumulation of PPV and FCV at 25 ˚C and
39 ˚C as a function of time was used to evaluate the effect of temperature on equilibrium
and assay sensitivity. These curves show that accumulation is increased at 39 ˚C,
presumably due to increases in mass transport arising from convection and larger
diffusion coefficients. Overall, it is shown that elevated temperatures are a simple method
for speeding up immunoassay extraction times and do not significantly compromise assay
performance. Total assay time can be reduced to less than 1 hour while retaining limits of
detection that are competitive with other methods.
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Table 1. Effect of temperature on solution viscosity and the diffusion coefficients for
mAb, PPV and FCV.
D (cm2/s)b x 10-7 
Temperature
(˚C)  (g/cm s)
a x 10-2 mAb PPV FCV
25 0.89 5.0 2.0 1.4
39 0.65 7.0 2.8 2.0
(a) Values from reference 36.
(b) Calculated using radii of 5, 12, and 18 nm for mAb, PPV and FCV respectively (see
text for further details).
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Figure 1. Theoretical accumulation of PPV, FCV, and mAb as a function of time at
different temperatures and a concentration of 1.0 x 1010 antigens/mL (17 pM).
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Figure 2. Plot of the derivative of Figure 1 with respect to time.
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Figure 4. AFM micrographs (5 x 5 µm2) and topographic cross-sectional plots of viruses
bound to capture substrates at 25 ˚C for 16 h for A) FCV (5 x 108 TCID50/mL), B) PPV
(6 x 106 TCID50/mL), and C) blank (10 mM PBS).
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Figure 5. Accumulation as a function of incubation time at 25 ˚C for a PPV
concentration of 8.9 x 109 virus particles/mL. The experimental data were obtained by
collecting AFM micrographs (5 x 5 µm) and averaging the number of enumerated PPV in
five separate locations. The experimental data were then fit to Equation 2, which yielded
 = 4.0t1/2 with an r2 value of 0.96. The theoretical curve was determined according to
Equation 2 by calculating  values at given times for a PPV concentration of 8.9 x 109
virus particles/mL, and a diffusion coefficient of 2.0 x 10-7 cm2/s (see Table 1).
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Figure 6. Accumulation as a function of incubation time at 39 ˚C for a PPV
concentration of 8.9 x 109 virus particles/mL. The experimental data were obtained by
collecting AFM micrographs (5 x 5 µm) and averaging the number of enumerated PPV in
five separate locations. The experimental data were then fit to Equation 2, which yielded
 = 7.7t1/2 with an r2 value of 0.97. The theoretical curve was determined according to
Equation 2 by calculating  values at given times for a PPV concentration of 8.5 x 109
virus particles/mL, and a diffusion coefficient of 2.8 x 10-7 cm2/s (see Table 1).
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Figure 7. Accumulation as a function of incubation time at 25 ˚C for a FCV
concentration of 1.0 x 1010 virus particles/mL. The experimental data were obtained by
collecting AFM micrographs (5 x 5 µm) and averaging the number of enumerated FCV
in five separate locations. The theoretical curve was determined according to Equation 2
by calculating  values at given times for a FCV concentration of 1.0 x 1010 virus
particles/mL, and a diffusion coefficient of 1.4 x 10-7 cm2/s (see Table 1).
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Figure 8. Accumulation as a function of incubation time at 39 ˚C for a FCV
concentration of 1.0 x 1010 virus particles/mL. The experimental data were obtained by
collecting AFM micrographs (5 x 5 µm) and averaging the number of enumerated FCV
in five separate locations. The theoretical curve was determined according to Equation 2
by calculating  values at given times for a FCV concentration of 1.0 x 1010 virus
particles/mL, and a diffusion coefficient of 2.0 x 10-7 cm2/s (see Table 1).
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Figure 9. Dose response curves for PPV at 25 ˚C for 16 h and 1 h and 39 ˚C for 1 h. The
data were obtained by collecting at least 5 AFM micrographs (5 x 5 µm) at each
concentration and averaging the number of PPV bound in the imaged area.
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Figure 10. Dose response curves for FCV at 25 ˚C for 16 h and 1 h and 39 ˚C for 1 h.
The data were obtained by collecting at least 5 AFM micrographs (5 x 5 µm) at each
concentration and averaging the number of FCV bound in the imaged area.
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ABSTRACT
Attomolar levels of detection were achieved for the analysis of porcine parvovirus
(PPV) in a sandwich immunoassay format by exploiting the sensitivity of surface-
enhanced Raman scattering (SERS) as a readout method and manipulating the area of the
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capture substrate and sample volume. The low level of detection was achieved by using a
two-fold approach. First, the area of the antibody-coated capture substrates was reduced
from 7.0 x 10-2 to 4.0 x 10-4 µm2. Second, the analyte volume was increased from 20.0 to
1000.0 µL. When coupled with surface-enhanced Raman scattering (SERS) and extrinsic
Raman labels (ERLs), a level of detection of 4.5 x 105 PPV/mL (750 aM) was realized.
Comparisons in limits of detection were made for larger sized (3-mm diameter) addresses
using the two extreme volumes to understand the performance trade offs. These findings
are also contrasted with those predicted from equilibrium considerations.
INTRODUCTION
Immunoassays are commonly used as diagnostic tests in human and veterinary
medicine.1 Current areas of focus have been on improving limits of detection, decreasing
time requirements and simplifying the methodology in order to provide healthcare with
tests to quickly and accurately provide diagnosis.2, 3 Some pathogens (e.g. E. coli
O157:H7, listeria, calicivirus, and avian influenza) can cause severe health problems like
gastroenteritis at very low levels of exposure,4-6 driving the need for ultra-sensitive
detection techniques.
Methods for virus detection include electron microscopy,7, 8 fluorescence-based
labeling,9, 10 polymerase chain reaction (PCR),11-16 atomic force microscopy (AFM),17-20
virus isolation,21 and serologic testing.22 However, these methods lack the sensitivity
needed for detecting single viruses6 (limits of detection ranging from 105 viruses/mL for
fluorescence9 to 108 viruses/mL for AFM detection19). To meet the demands of diagnosis
for certain viruses and bacteria, lower levels of detection must be realized.
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To reach ultra-low levels of detection, a high surface concentration of antigen
bound to the sensor area is desirable, especially for readout methods that do not
interrogate the entire sensor area. As an example, if the sensor area is 0.070 cm2, the laser
area is 4.5 x 10-6 cm2, and the size of a virus is 25-nm in diameter (Scheme 1), only a
small percent of the sensor area is interrogated by the laser. In order to achieve ultra-low
limits of detection, then, the highest surface concentration of bound antigen for any given
initial antigen concentration is desirable. Examination of the sensor area, sample volume,
and equilibrium constant on the surface concentration of bound antigens, will provide
insight into the conditions needed to achieve the highest surface concentrations of
antigen, and therefore the lowest limits of detection. To achieve this condition, it is
desirable to apply the principles of negligible depletion in order to retain the binding
affinity of the capture antibody.23 Depletion of the free concentration of analyte causes
changes in the equilibrium, which in turn, affects the concentration of analyte that can be
extracted.24
In this paper, we seek to understand the gains achieved by using small capture
substrates and large sample volumes to detect low levels of porcine parvovirus (PPV). To
study the effect of sample volume on the SERS signal for detection of PPV, three tests
were performed. In the first two tests, large (0.071 cm2) capture substrates were exposed
to either small (20.0 µL) or large (1.0 mL) volumes of PPV and ERL solutions. For the
third test, small capture substrates (4.0 x 10-4 cm2) were treated with large volumes (1.0
mL) of PPV and ERL solutions. In each case, calibrations curves were constructed, and
signal strengths and limits of detection were compared. The small gold substrates were
fabricated on pyrex wafers and then modified with monoclonal antibodies specific for
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porcine parvovirus (anti-PPV mAbs). Large gold substrates were also modified with anti-
PPV mAbs, and the immunoassay procedure for both substrate sizes follows that
previously optimized in our laboratory.25 ERLs were constructed using 60-nm gold
nanoparticles coated with an intrinsically strong Raman scatterer to provide the spectral
signature, and anti-PPV mAbs to provide biorecognition. Since large biomolecules have
small diffusion coefficients,26 the viruses and ERLs were allowed to diffuse to the capture
substrates for 24 h in an attempt to establish equilibrium.
SERS has been shown to be a sensitive readout method, and therefore provides a basis to
push the envelope for ultra-low levels of detection. Current levels of detection for SERS
readout methods are in the femtomolar regime, and for virus detection with SERS the
current level of detection is 1 x 106 viruses/mL.25 Previous studies in our laboratory have
shown that as few as ~60 binding events can be detected using 30-nm gold nanoparticles
with limits of detection of ~30 fM for prostate specific antigen in human serum.27 We
would like to exploit this sensitivity and reach far lower levels of detection by
capitalizing on the high surface concentrations of antigen achieved with small capture
substrates and large volumes.
THEORETICAL CONSIERATIONS
Equilibrium Model for Heterogeneous Immunoassays. We have modeled the
equilibrium for a heterogeneous immunoassay as a function of the capture substrate
surface area and the volume of the sample solution to determine the ideal conditions to
reach low levels of detection. As a starting point, the equilibrium for a 1:1 binding
stoichiometry can be expressed by3:
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Agsoln + Absurf  AgAbsurf (1)
where Agsoln is the antigen in solution, Absurf is the uncomplexed antibody immobilized on
the surface, and AgAbsurf is the antibody-antigen complex on the surface. The equilibrium
constant, K (L/mol), for a heterogeneous assay is defined as:
[ ] Absol
AgAb
Ag
K


= (2)
where AgAb is the equilibrium surface concentration of bound antigen (mol/cm2), [Ag]sol
is the equilibrium solution concentration of antigen (mol/L), and
Ab is the equilibrium surface concentration of uncomplexed antibody (mol/cm2). Since
the equilibrium in Equation 1 involves a liquid and solid phase, a full accounting of the
system must include the area of the capture substrate, A, and the volume of the sample
solution, V. The equilibrium concentration for the antigen in solution can then be written
as:
[ ]
V
ACV
Ag AgAb
sol
	
= (3)
where C is the initial antigen solution concentration. By mass balance, we can determine
Ab via Equation 4 :
Ab = Ab,i - AgAb (4)
where Ab,i  is surface concentration of the initial antibody immobilized on the capture
substrate. By substituting Equations 3 and 4 into Equation 2 and rearranging, we obtain:
KAAgAb2 + (- V - KCV - KAAb,i)AgAb + KCVAb,i = 0 (5)
By using the quadratic equation, we can solve for AgAb as a function of several important
experimental parameters (i.e., C, V, A, and K).
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Table 1 summarizes the values of the key parameters that will be used to model
the heterogeneous equilibrium. These values reflect, in part, the design of our
experimental assay platform, including estimates of Ab,i and possible values of K. Some
of the values, however, were included in order to more fully delineate the intricacies of
the equilibrium. The remainder of this section examines the impact of these parameters
on the performance of an assay, focusing specifically on how to push the LOD to lower
values.
As a starting point, the effect of K and C on AgAb was examined using our 3-mm
diameter capture substrate (A = 0.070 cm2) and a 1.0-mL sample. These results are
presented in Figure 1. For all values of K, the dependence of AgAb on C has the sigmoid-
like shape expected for a typical distribution plot,3, 28 which arises from a shift in the
heterogeneous equilibrium towards an increase in the absolute amount of antigen
captured by the immobilized antibodies. A more detailed examination of these plots
reveals three additional points. First, the profiles all reach the same upper value for AgAb.
This result reflects the limitation imposed by the surface concentration of capture
antibodies (6.7 x 10-13 mol/cm2, see Table 1).29
Second, the profiles all move to larger values of C as K decreases. This trend
highlights the impact of the affinity between the antigen and immobilized antibody on the
LOD. If, for example, the readout technique can detect a AgAb of 6.7 x 10-14 mol/cm2, the
LOD at a K of 1.0 x 107 would be ~1 x 10-8 M. Furthermore, the plots show that a
decade-increase in K lowers the LOD by a factor of ten.
Third, the above trend holds until moving up to a K value of 1010. Above K values
of 1010 the improvement in LOD with increases in K drops dramatically. From a
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graphical perspective, this change corresponds to a marked deterioration in the shape of
the plots in Figure 1 in that as K becomes larger, the profile becomes more truncated. The
truncation in shapes arises from a perturbation in the initial concentration of the antigen
solution, C, from the extraction of antigens by the capture substrate. As a consequence,
the surface concentration of the antigen-antibody complex is not pushed to the level that
would be achieved in the absence of any depletion of the initial antigen solution
concentration, and the LOD is higher than would be the case in the absence of depletion.
The importance of depletion and its connection to sample volume are examined in
more detail in Figures 2A-C. These plots summarize the effect of sample volume (20-
1000 µL) and the equilibrium constant (109 – 1013) on AgAb. In general, the profiles have
a shape that becomes increasingly truncated as volume decreases and K increases. Both
trends can be attributed to how the experimental conditions affect depletion. That is,
larger volumes and smaller values of K will not be as sensitive to depletion as test
conditions at smaller sample volumes and larger values of K. The plots in Figure 2 also
illustrate how the sample volume affects the LOD. At each value of K, the LOD
decreases as the sample volume increases. Moreover, the ideal case for detection at a
given value of K occurs when depletion is negligible. This situation is demonstrated by
the coalescence of the plots in Figure 2A. This coalescence corresponds to an assay that
is independent of sample volume, i.e., an assay carried out in a negligible depletion
mode.23, 24, 30
One approach to alleviate the dependence of volume on the number of antigens
bound at equilibrium would be to use a capture substrate with a smaller area and a sample
with a larger volume. At small capture substrate areas (4.0 x 10-4 cm2) and large sample
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volumes (1.0 mL), different values of K show the expected sigmoid shape (Figure 3), and
truncation is not as pronounced as when large capture substrates are used. The profiles
for the small capture substrates reach the same upper limit of AgAb, that is found for the
large capture substrates, a consequence of both models being assigned the same value for
Ab,i. For a sensor area of 4.0 x 10-4 cm2, and a K value of 1.0 x 1011, the surface
concentration of antigen bound, AgAb is plotted in Figure 4 with respect to the initial
antigen concentration, C. The curves deviate only slightly when small volumes are used,
suggesting that small capture substrate areas provide a means to achieve high surface
concentrations of antigen at low sample volumes by reducing the effect of depletion.
The importance of volume on the equilibrium of the system can be expressed by
calculating the values required to prevent perturbation of the initial antigen concentration.
For our purposes, we have defined the volume for minimal depletion as that which
upholds the condition, [Ag]soln = 0.09C. The results of this calculation for different K and
C values are shown in Figure 5. Figure 5A and 5B show the volume necessary to prevent
sample depletion for large and small capture substrates, respectively. Higher values of K
require larger solution volumes to prevent depletion, an observation that is more
pronounced for low initial antigen concentrations. To remain volume independent, and
thus achieve the highest surface bound antigen concentrations (Figures 2 and 4), larger
volumes are required for larger capture substrates as compared to smaller capture
substrates. An additional consequence of this observation is that the reproducibility of the
assay is more sensitive to variations in small volumes with larger capture substrates. The
next several sections detail experiments designed to explore these predictions.
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EXPERIMENTAL
Reagents. Anti-PPV mAbs were provided by National Animal Disease Center
(NADC; Ames, IA) as a 1.0 mg/mL stock and were purified with a protein G column
(Pro-Chem) to 99.9% purity. PPV stock solutions were also supplied by NADC in
phosphate buffered saline (PBS) with a concentration of 3.2 x 109 TCID50/mL. The
conversion factor for PPV from TCID50/mL to virus particles/mL is ~1400 and was
derived from fitting experimental curves of PPV accumulation with respect to rotation
rate.31
Gold nanoparticles (60 nm, 2.6 x 1010 particles/mL) were purchased from Ted
Pella. Octadecanethiol (ODT), PBS packs (10 mM), sodium chloride,
dithiobis(succinimidyl propionate) (DSP), and bovine serum albumin (BSA) were
purchased from Sigma. Superblock and borate buffer packs (50 mM) were received from
Pierce. 5,5’-dithiobis(succinimidyl-2-nitrobenzoate) (DSNB) was synthesized according
to literature.27
ERL Preparation. ERLs integrate a strong Raman scatterer with an
immunorecognition element such as an antibody. DSNB was designed as the Raman
reporter molecule because of its inherently strong Raman scattering cross section due to
the symmetric stretch of the nitro group tethered to an aromatic ring. In addition, DSNB
spontaneously adsorbs to the gold nanoparticles through cleavage of the disulfide moiety
and covalently attaches antibodies to the succinimidyl ester group by forming an amide
bond with the amine groups found on antibodies.
To prepare 1.0 mL of ERLs, the pH of the 60-nm gold nanoparticle solution was
adjusted to 8.5 by adding 40.0 µL of 50 mM borate buffer. The nanoparticles were then
97
coated with DSNB by adding 10 µL of 1 mM DSNB in acetonitrile and mixing for 8 h.
For immunospecificity of the colloidal solution, 20 µg of anti-PPV mAb was added to the
suspension for ~12 h. Finally, the colloidal suspension was stabilized and blocked by
adding 10% BSA in 2 mM borate buffer (100.0 µL) for 6 h. For removal of residual
proteins and DSNB, the nanoparticles were centrifuged at 2000 g for 10 min. The
supernatant was decanted, and the particles were resuspended in 1.0 mL of 2 mM borate
buffer containing 1% BSA. This rinsing cycle was repeated twice to thoroughly remove
any excess reagents. In the final resuspension step, 100.0 µL of 10% NaCl was added to
the 1.0 mL suspension to reach a final physiological salt concentration of ~150 mM.
Aggregates were removed by passage of the solution through a 0.22-µm syringe filter
(Costar).
Preparation of Small Area Capture Substrates. The small area (200 x 200 µm)
substrates were prepared using conventional photolithographic and metal lift-off
techniques. A 0.5-mm thick pyrex wafer (University Wafer) was first coated with
positive photoresist (AZ4330, Clariant) at 2000 rpm for 30 s and then softbaked at 110 ˚C
for 1 min. The resist-coated wafer was then exposed to UV light for 4 s through a
photomask and post-exposure baked for 1 min at 110 ˚C. The wafer was subsequently
immersed in developer (3:1 water:Shipley 351 developer) for 2 min. Next, the patterned
wafer was coated with an 8-nm titanium adhesion layer (0.1 nm/s), followed by a 75-nm
layer of gold (0.1 nm/s). Lift-off of the gold-coated photoresist was achieved by
sonication in acetone (Fisher) and an ethanol post rinse. The substrates were finally dried
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with a stream of high-purity nitrogen. The wafers were then cut into 1 x 1 cm sections by
American Dicing.
To modify the sample squares with a linker molecule to covalently immobilize the
capture antibody, the squares were first cleaned with a 40-W argon plasma for 1 min at 1
Torr and then immediately placed in a 0.1 mM ethanolic solution of DSP for ~5 h. The
samples were then rinsed with ethanol and dried under high-purity nitrogen.
Preparation of Large Area Capture Substrates. Microscope slides (Fisher) cut
to 1 x 1 cm were cleaned sequentially in an ultrasonic bath in diluted Contrad 70,
deionized water, and ethanol for 30 min each. Then, the clean glass chips were placed in
an Edwards 306A resistive evaporator. First a chromium adhesion layer (~10 nm) was
resistively evaporated onto the glass chips followed by ~250 nm of gold (99.9% purity) at
a rate of 0.1 nm/s. To create a capture substrate of the appropriate size, a piece of PDMS
with a 3-mm diameter hole cut out of the center was soaked in an ethanolic ODT solution
for ~1 min and placed on the clean gold substrates for ~30 s. The stamp was removed,
and the substrates were rinsed with ethanol and placed in a 0.1 mM ethanolic solution of
DSP for ~12 h. Finally, the substrates are rinsed with ethanol and dried with high purity
nitrogen. The ODT adlayer creates a hydrophobic barrier that confines sample solutions
to a 3-mm diameter circle. The DSP-derived adlayer covalently couples the mAbs to the
gold substrate.
Immunoassay Protocol. Immunospecificity was achieved by pipetting an anti-
PPV mAb solution (20.0 µL, 100 µg/mL in 50 mM borate buffer (pH 8.5)) over the 200 x
200 µm gold squares or in the 3-mm capture area for ~12 h in a humidity chamber. The
samples were then rinsed by submerging them sequentially three times in fresh 10 mM
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PBS (3 mL). The samples were then placed in 1.0 mL or 20.0 µL of SuperBlock blocking
buffer for ~8 h and then rinsed with 10 mM PBS. PPV samples were diluted in 10 mM
PBS, and the samples were immersed in 1.0 mL or 20.0 µL of each PPV concentration
for ~24 h. The samples were rinsed three times with 2 mM borate buffer containing 150
mM NaCl and then exposed to 1.0 mL or 20.0 µL of prepared ERLs and incubated for
~12 h. After ERL binding, the substrates were rinsed with 2 mM borate buffer (150 mM
NaCl) three times and then dried with a stream of high purity nitrogen. SERS spectra
were then obtained for each substrate.
Instrumentation. A NanoRaman I fiber-optic-based Raman system (Concurrent
Analytical) was used to collect the Raman spectra. The light source was a 30-mW, 632.8-
nm He-Ne laser; the spectrograph was a f/2.0 Czerny-Turner imaging spectrometer (6-8
cm-1 resolution); and a Kodak 0401E CCD thermoelectrically cooled to 0 ˚C. The
incident laser light (normal incidence) was focused to a 25-µm spot size on the 200 x 200
µm gold squares or in the 3-mm diameter sensor area. The objective has a numerical
aperture of 0.68, and the power at the sample was ~3 mW. The same objective was used
to collect the scattered radiation. Spectra were obtained with 1-s integration.
RESULTS AND DISCUSSION
Three tests were performed in order to assess the effect of the area of the capture
substrate and volume of the sample on the concentration dependent signal strength and
LODs. Two tests used our 3-mm diameter addresses and either 1.0-mL or 20.0-µL
sample volumes. The third reduced the address size to 200 x 200 µm (4.0 x 10-4 cm2) and
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a 1.0-mL sample. For each experiment, SERS spectra were collected for various
concentrations of PPV, with 24-h incubations employed in both the capture and ERL
labeling steps. In all cases, the spectra show features that are consistent with the Raman
reporter molecule, DSNB (e.g., the symmetric nitro stretch, s(NO2) at 1336 cm-1 and an
aromatic ring mode at 1558 cm-1), and have signal strengths proportional to PPV
concentration. The intensity of s(NO2) was averaged from five different locations on
each substrate in order to construct dose-response curves. The standard deviations in
these plots are represented by the error bars.
Based upon the model, the expected surface concentrations of antigens at an
initial antigen concentration of 1.0 x 10 -17 M for the three tests performed are delineated
in Table 2 for two values of K. As detailed in the table, small capture areas and large
sample volumes are expected to yield the highest signals and the least sample depletion.
The experimental results are presented below.
Test I. Large capture substrate area, small sample volumes. In this
experiment, SERS spectra were collected for large area capture substrates (0.071 cm2)
using small volumes (20.0 µL) of virus and ERLs. Figure 6 presents spectra for
concentrations up to 2.0 x 1010 PPV/mL. The dose-response curve from these spectra is
found in Figure 7, which shows a leveling-off in signal about 9.0 x 109 PPV/mL. An
analysis of these data yields a LOD of 2.1 x 107 PPV/mL. Interestingly, there is no
detectable non specific binding of the ERLs in this set of experiments, an ideal, but only
occasionally realized situation. Thus the blank signal is determined only by the noise in
the measurement.
101
Test II. Large capture substrate area, large sample volume. This test used
large substrates (0.071 cm2 capture area) and large sample volumes (1.0 mL) of PPV and
ERLs. The SERS spectra are shown in Figure 8 and the dose-response curve is given in
Figure 9. There are two main observations to draw from this data. First, these samples all
exhibit a detectable level of non-specific adsorption. However, we have not been able to
determine why this proved problematic with these samples but not those in Test I.
Second, the strength of the signal for these samples is larger than those prepared using the
20.0-µL sample volumes (Figure 6). For example, the response for a 1.0-mL sample at
4.5 x 108 PPV/mL, after accounting for the background signal, is more than five times
stronger than that for the analogous 20.0-µL sample. We attribute this difference to how
the sample volume alleviates depletion, and pushes a larger absolute number of antigens
onto the capture substrate. Analysis of these data yields a LOD of 4.2 x 107 PPV/mL.
Test III. Small capture substrate area, large sample volume. Finally, 200 x
200 µm addresses, which are 1.4 x 10-3 times smaller in area than the 3-mm diameter
addresses, were exposed to 1.0-mL of PPV and ERL solutions. The goal is to examine
how much of an increase in PPV surface concentration will be realized by a reduction in
the surface area of the capture substrate, which would be driven by a lower level of
antigen depletion in the 1.0-mL sample. The SERS spectra and dose-response plot are
presented in Figures 10 and 11, respectively. A comparison to the data in Figure 8 shows
that the expectation of a larger signal is achieved. That is, the response for the exposure
to 1.0-mL of 4.5 x 107 PPV/mL solution is 3086 cts/s (after accounting for the average
blank signal) for the small address and only 2594 cts/s with the larger address. Moreover,
if a linear dependence is assumed for the signals of Test I, the same sample
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concentration, would yield only 103 cts/s at a 20.0-µL volume. In this case, the signal
obtained from Test III is ~30 times greater than that projected for Test I. Taken together,
the assay with the small sized capture addresses yields a LOD of 4.5 x 105 PPV/mL or
750 aM. Performance can also be cast within the context of TCID50 units, which is a
quantile measure of pathogenicity. By this measure, the LOD translates to 320
TCID50/mL.
Further examination of the implications of the results in Figures 6-11 can be
developed by establishing a correlation between the SERS response and number of bound
virus particles. For this purpose, the dose-response curves in Figure 8 can be compared
with that from a recent investigation that enumerated the capture of PPV (3-mm address,
20.0-µL sample) by atomic force microscopy (AFM).32 Figure 12 summarizes both sets
of data, noting that the AFM-based findings were extrapolated from 5 x 5 µm image sizes
to the area interrogated by the 25-µm diameter laser spot size in the SERS experiments.
Like the SERS data, the enumeration by AFM undergoes a linear increase at low PPV
concentrations. Thus, the correlation between the two plots shows that the SERS signal
for each captured virus is ~4 cts/s.
This correlation can then be used to delineate the number of viruses that give rise
to the signal of the LOD for SERS measurements. Table 3 summarizes the analysis of the
spectral data from all three tests, and includes estimates of the percentage of PPV
depletion as a consequence of the capture step. The Table also projects the number of
viruses in the laser focal area at levels approaching and below the LOD, and is given
parenthetically. In each case, less than 100 viruses give rise to the signal at the LOD. The
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Table also underscores the merits of minimizing sample depletion in reaching the LOD
found for the small capture substrate/large volume (S/L) assay.
CONCLUSIONS
The lowest concentration of PPV studied in Test I (4.5 x 108 PPV/mL) gives a
SERS signal of 1028 ± 91 cts/s. In comparison, the highest concentration of PPV studied
in Test III (4.5 x 107 PPV/mL) gives a SERS signal of 3220 ± 286 cts/s, an improvement
of 30 times. The limit of detection for large capture areas and small sample volumes is
100 times greater when small capture substrates and large volumes are employed. This
improvement is attributed to the higher surface concentration of captured viruses
achieved by conducting the analysis in a negligible depletion mode.
Non-specific binding plays a key role in the determination of limits of detection,
often dictating the experimental limit of detection. As is seen in the findings herein, a
lower level of detection is found in Test I as compared Test II largely because the non-
specific binding is higher for Test II. The blank signal for the large substrate and small
sample volumes is effectively immeasurable, that is, no non-specific binding could be
detected. In comparison, the blank signal for Test II is 821 ± 142 cts/s and that for Test
III is 134 ± 41 cts/s.
The use of small substrates exposed to large sample volumes allows for attomolar
detection of viruses through increasing the surface bound concentration of viruses at low
virus concentrations. However, a challenge remains in that the level of performance
requires long incubation times. As has been recently shown, this difficulty can be
overcome by substrate rotation31 and elevations in temperature.33 By combining substrate
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rotation with small capture areas and large sample volumes to allow the highest surface
bound concentration of antigen, and using the ultra-sensitive readout method of SERS,
ultra-low levels of detection for pathogens can be achieved in relatively short times,
providing an attractive method for diagnosis/identification in the event of an outbreak.
These results emphasize that in order to realistically detect ultra-low levels of detection,
large sample volumes and/or small capture substrates are clearly preferred embodiments.
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Laser Spot Size (25 µm diameter)
Capture Substrate
(3.0 mm diameter)
PPV (25 nm diameter)
0.22 mm
diameter
0.007 mm
diameter
Scheme 1. Depiction (drawn to scale) of the size of the laser compared to a large capture
substrate area (0.070cm2).
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Table 1. Model Parameters for Equilibrium Predictions.
Parameter Range of Modeled Values
K (L/mol)a 1.0 x 107 – 1.0 x 1013
A (cm2)b 7.0 x 10-2 and 4.0 x 10-4 
V (µL)b 20.0-1000.0
C (M)c 1.0 x 10-18 – 1.0 x 10-6 
Ab,i (mol/cm2)d 6.7 x 10-13
a) Reference 3
b) We typically used 20 and 40-µL sample volumes and 3.0-mm diameter capture
addresses in our assays, but expanded the volume to 1 mL and decreased the
address to 200 x 200 µm as possible approaches to improve the LOD.
c) The lower limit represents values found in this work.
d) This value represents an estimate based on the closest-packing of the immobilized
antibodies and a ~30% viability after immobilization. The latter accounts for the
observed viability of immobilized antibodies, as detailed by Shannon and co-
workers (reference 29).
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Figure 1. The effect of the equilibrium constant, K, and the initial concentration of
antigen, C, on the surface concentration of antigens bound to the capture substrate, AgAb.
Capture substrate area: 0.070 cm2; sample volume: 1.0 mL.
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Figure 2. Effect of sample volume, V, on the surface concentration of captured antigen,
AgAb, for a capture substrate area of 0.070 cm2 and equilibrium constants, K, of (A) 1.0 x
109, (B) 1.0 x 1011, and (C) 1.0 x 1013.
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Figure 3. The effect of the equilibrium constants, K, and the initial concentration of
antigen, C, on the surface concentration of antigens bound to the capture substrate, AgAb.
Capture substrate area: 4.0 x 10-4 cm2; sample volume: 1.0 mL.
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Figure 4. Effect of sample volume, V, on the surface concentration of captured antigen,
AgAb, for a capture substrate area of 4.0 x 10-4 cm2 and equilibrium constants, K, of (A)
1.0 x 109, (B) 1.0 x 1011, and (C) 1.0 x 1013.
113
K (L/mol)
100 101 102 103 104 105 106 107 108 109 1010 1011 1012 1013 1014
Vo
lu
m
e
( µL
)
0
10000
20000
30000
40000
50000
1 x 10-9
1 x 10-10
1 x 10-11
Vo
lu
m
e
(µL
)
0
100
200
300
400
Vo
lu
m
e
( µL
)
Vo
lu
m
e
(µL
)
A
K (L/mol)
100 101 102 103 104 105 106 107 108 109 1010 1011 1012 1013 1014
Vo
lu
m
e
( µL
)
0
50
100
150
200
250
1 x 10-9 M
1 x 10-10 M
1 x 10-11 M
Vo
lu
m
e
(µL
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Vo
lu
m
e
( µL
)
Vo
lu
m
e
(µL
)
B
Figure 5. Volume, V, required to keep the equilibrium concentration of antigen in
solution at 90% of the initial concentration of antigen for different equilibrium constants,
K, and different initial concentrations, C, at capture substrate areas, A, of (A) 0.070 cm2
and (B) 4.0 x 10-4 cm2.
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Table 2. Tabulated values given an initial antigen concentration, C, of 1.0 x 10-17 M.
K CaptureArea
Sample
Volume
Total
Antigens
Surface
Conc. of
Antigens
Total
Captured
Antigens
Antigens
in Laser
Spot
%
Depletion
(L/mol) (cm2) (µL) (particles) (mol/cm2) (particles) (particles)
0.070 20.0 120 2.8 x 10-21 120 0.009 100
1011 0.070 1000.0 6020 1.2 x 10-19 4962 0.35 82.4
0.0004 1000.0 6020 6.5 x 10-19 157 2.0 2.6
0.070 20.0 120 2.9 x 10-21 120 0.009 100
1013 0.070 1000.0 6020 1.4 x 10-19 6007 0.43 99.8
0.0004 1000.0 6020 1.8 x 10-17 4384 54.8 72.8
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Figure 6. SERS spectra for a sandwich immunoassay using a 3-mm diameter capture
substrate and 20.0-µL incubations in both the PPV capture step and the ERL labeling
step.
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Figure 7. Dose-response plot using the intensity of the s(NO2) for a sandwich
immunoassay using a 3-mm diameter capture substrate and 20.0-µL incubations in both
the PPV capture step and the ERL labeling step.
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Figure 8. SERS spectra for a sandwich immunoassay using a 3-mm diameter capture
substrate and 1.0-mL incubations in both the PPV capture step and the ERL labeling step.
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Figure 9. Dose-response plot using the intensity of the s(NO2) for a sandwich
immunoassay using a 3-mm diameter capture substrate and 1.0-mL incubations for both
the PPV capture step and the ERL labeling step.
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Figure 10. SERS spectra for a sandwich immunoassay using a 200 x 200 µm capture
substrate and 1.0-mL incubations in both the PPV capture step and the ERL labeling step.
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Figure 11. Dose-response plot using the intensity of the s(NO2) for a sandwich
immunoassay using 200 x 200 µm capture substrate and 1.0-mL incubations in both the
PPV capture step and ERL labeling step.
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Figure 12. Dose-response curves for SERS-based (circles) and AFM-based (squares)
detection of PPV on capture substrates with an area 0.070 cm2, and a sample volume of
20 µL. The SERS calibration curve is constructed with the intensity of the nitro band at
1336 cm-1, the data points representing the average signal from five different locations on
the same sample. Each AFM data point is the average number of PPV bound from five
images collected for each sample.
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Table 3. Number of viruses interrogated by the laser and the % PPV left in solution as a
function of concentration, capture substrate area, and sample volume. L/S: 0.070-cm2
capture area, 20.0-µL sample volume, L/L: 0.070-cm2 capture area, 1.0-mL sample
volume; and S/L: 4.0 x 10-4 cm2-capture area, 1.0-mL sample volume.
# PPV in Laser % PPV in solution
PPV/mL TCID50/mL L/S L/L S/L L/S L/L S/L
2.2 x 1010 16000000 6178 81
9.0 x 109 6400000 5527 57
4.5 x 109 3200000 2675 5969 58 98
9.0 x 108 640000 622 2013 51 97
4.5 x 108 320000 257 1539 60 95
4.5 x 107 32000 (26) 854 805 73 99
4.5 x 106 3200 (3) (85) 310 99
4.5 x 105 320 (0.3) (9) 76 99
4.5 x 104 32 (0.03) (0.9) 36 94
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ABSTRACT
Aptamers are potential alternatives to antibodies as molecular recognition
elements. We present herein a comparison of antibodies and aptamers as capture reagents
in a surface-enhanced Raman scattering (SERS) based assay for thrombin by using
thrombin binding aptamer (TBA) and sheep-anti-human thrombin antibody. The
conditions employed for an aptamer-based assay, much like antibody assays, are central
to performance and require extensive optimization. This work examined how TBA
immobilization and binding buffer composition affected assay performance. The
procedure for immobilization of TBA on a gold substrate was optimized by addition of a
spacer reagent (6-mercapto-1-hexanol (MHx)), which reduced electrostatic interactions
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between the DNA (aptamer) backbone and the gold substrate, and promoted TBA
orientation along the surface normal to the substrate. The optimal concentrations of TBA
and MHx were determined to be 10 µM each, with MHx being allowed to displace TBA
for 1 h. Next, the binding buffer composition for extraction of thrombin was analyzed by
addition of cations that are known to stabilize the TBA quadruplex structure required for
thrombin binding. The addition of 1 mM MgCl2 and 100 mM KCl to the 10 mM PBS
binding buffer was found to impart little improvement on thrombin binding. Limits of
detection using antibody and aptamer as capture reagents were 30 pM and 200 pM,
respectively. Finally, as a test of the robustness, both capture substrates were dried and
stored for 48 h without significant compromises to sensitivity.
INTRODUCTION
Aptamers were discovered independently in 1990 in the laboratories of Joyce,1
Szostak,2 and Gold3 using an in vitro selection and amplification method termed SELEX
(Systematic Evolution of Ligands by Exponential Enrichment). The invention of SELEX
subsequently triggered the development of small oligonucleotides (40-100 bases) that
bind non-nucleic acid targets with specificities and affinities that rival those of antibodies
(Abs).4 With SELEX, aptamers have been selected for a variety of targets, ranging in size
from small organic molecules to proteins.5-7 The ability to discriminate between
enantiomers has also been reported.8
Aptamers offer several potentially distinct advantages over antibodies. Aptamers
can be produced and purified synthetically,9, 10 eliminating the use of animals. In
addition, the types of targets that can be screened with aptamers is far greater than with
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antibodies, and includes materials that are toxic or non immunogenic. Furthermore,
screening begins with a larger pool of oligonucleotides (1013-1018 sequences per
experiment),9 while antibodies are limited to the diversity of IgG and IgM molecules and
can be challenged by batch to batch variations.9, 11 Moreover, the chemical simplicity of
aptamers facilitates long term storage without denaturation and degradation,9 and use
under physiological conditions is not required. Finally, aptamers can be engineered more
easily than antibodies to incorporate site-specific labels that do not affect their affinity
(affinities range from 1 pM – 1 µM).10, 12 In contrast, antibodies are only stable in
physiological environments and the addition of labels can affect their affinities.
Although aptamers have some distinct advantages over antibodies, there are also
some drawbacks. They are susceptible to nuclease attack, especially RNA aptamers,
which limits their lifetime. In addition, since binding depends on the aptamer adopting a
specific three-dimensional conformation, optimization requires a case-by-case study.
Some of the parameters that must be taken into consideration are use of stabilizing
cations, buffer composition, immobilization procedure with heterogeneous assays, and
temperature (i.e., must be below the melting temperature).9
Thrombin binding aptamer (TBA = 5’-GGTTGGTGTGGTTGG) was the first
aptamer developed in-vitro for a non-nucleic acid binding protein, and has been
extensively studied and characterized.13-18 It has binding affinities ranging from 25-200
nM.10, 13-18 TBA forms a unimolecular quadruplex structure consisting of a stack of two
guanine quartets that is stabilized by cations such as K+, Pb+, Ba2+, and Sr2+.15, 16
Thrombin is thought to bind adjacent to the two TT loops that connect the G-quartets.10
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TBA has been employed in many bio-sensing applications, including an enzyme
linked aptamer assay (ELAA)9, 18 and a molecular beacon concept.12, 19 Other promising
methods for “aptasensor” development include the use of electrochemical,20-22
impedimetric,23 fluorescence,10 optical,24 and mass25 based schemes. Detection limits of 1
nM were achieved using a mixed ELISA/ELAA sandwich format,18 and evanescent-
wave-induced fluorescence anisotropy.10 We report herein on a sandwich aptamer assay
for thrombin using surface enhanced Raman scattering (SERS) for readout. SERS is
emerging as a highly versatile technique for the detection of biomolecules, including
viruses and cancer markers (e.g., prostate specific antigen), and can reach femtomolar
detection limits.26, 27
This paper examines the potential merits of combining SERS and aptamers as
assay platforms. To this end, it compares and contrasts the use of TBA and thrombin
antibodies to capture thrombin. Labeling of thrombin for SERS detection relied on the
fabrication of extrinsic Raman labels (ERLs) that contain a Raman active molecule and
an antibody specific for thrombin (Scheme 1). Our method begins with a capture surface
constructed of TBA, modified with a six-carbon linking chain and a thiol group,
immobilized on a gold surface. The architecture of the adlayer is then modified by
immersion of the substrate in a dilute solution of 6-mercapto-1-hexanol (MHx), which
coadsorbs on the gold surface and/or displaces TBA. This “capping” step is necessary in
order to overcome the electrostatic interactions with gold that disrupt the TBA
quadruplex structure. The capture surface is next exposed to thrombin. Finally, ERLs
coated with sheep-anti-thrombin antibody solutions are used to selectively tag the
captured thrombin. Conditions, including salt concentration and MHx concentration, for
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the aptamer assay were optimized and limits of detection were calculated. The antibody-
based assay follows a course similar to that for the aptamer-based assay, with antibodies
covalently immobilized to the gold substrate used as the capture substrate.
EXPERIMENTAL
Reagents. TBA, supplied by Sigma Genosys, was modified on the 3’ end with a
six carbon linking chain and terminated on the distal end by a thiol (5’-
GGTTGGTGTGGTTGG[6THS]) which directs the immobilization on the gold surface.
Thrombin (37 kDa) from human serum (1000 National Institute of Health (NIH)
units/mL, 0.10 mg/mL), phosphate buffer saline (PBS) packs (10 mM, pH 7.2), bovine
serum albumin (BSA), octadecane thiol (ODT), dithio-bis succinimidyl proprionate
(DSP), and MHx were acquired from Sigma Aldrich. Borate buffer packs (50 mM, pH
8.5) and SuperBlock were from Pierce, while KCl, MgCl2, and NaCl were from Fisher.
Sheep-anti-human thrombin antibody was purchased from US Biologicals. Gold
nanoparticles (60 nm, 2.6 x 1010 particles/mL) were from Ted Pella and DSNB [5,5’-
dithiobis(succinimidyl-2-nitrobenzoate] was synthesized according to a literature
procedure.26 Contrad 70 (Decon Labs), a mild detergent, was used to clean the glass
substrates. Poly(dimethyl siloxane) (PDMS, Dow Corning) was utilized to prepare
microcontact printing stamps.
ERL preparation. ERLs are designed to package immunospecificity and provide
a strong Raman scattering signal. The use of the thrombin antibody imparts specificity,
whilst DSNB coats the nanoparticles with a strong Raman scatterer. DSNB is a key
ingredient in ERL development due to: 1) the inherently strong Raman scattering cross
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section of its symmetric nitro stretch; 2) its ability to chemisorb to gold surfaces through
sulfur-gold interactions; and 3) its facility to covalently immobilize amine containing
compounds (i.e., the reaction of antibodies with the succinimidyl ester).
ERLs are constructed by combining 40.0 µL of 50 mM borate buffer and 1.0 mL
of 60-nm gold nanoparticles in order to adjust the pH to 8.5, which deprotonates the
amine groups of the antibodies that are added in subsequent steps. Next, 10.0 µL of 1.0
mM DSNB in acetonitrile are mixed into the suspension and allowed to react for ~12 h
and thereby form a DSNB-derived monolayer on the particles. Sheep-anti-human
thrombin (100 µL of a 0.20 mg/mL solution in 2 mM borate buffer) was then added to
the suspension and reacted with the succinimidyl groups on DSNB for ~8 h to form an
amide linkage. Next, BSA (100 µL of 10% in 2 mM borate buffer) acting as
blocking/stabilizing agent was added to the mixture. After ~ 12 h the suspension was
centrifuged at 2000 g for 10 min to remove excess reagents and was re-suspended in 1.0
mL of 2 mM borate buffer with 1% BSA. This cleanup procedure was repeated twice
with a final, 500 µL suspension of 2 mM borate buffer, 1% BSA, and 150 mM NaCl;
NaCl is used to mimic physiological conditions. Finally, the ERLs were passed through a
0.22-µm syringe filter (Costar) to remove any large aggregates. Subsequent tests showed
that the antibody-modified particles remained stable as suspensions and active as labels
for at least 5 months when stored at 4 ˚C.
Gold Chip Preparation. Glass microscope slides (Fisher) were cut into 1 x 1 cm
squares and ultrasonically cleaned in 10% Contrad 70, deionized water, and ethanol for
30 min each. The squares were dried with nitrogen and placed in a resistive evaporator
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(Edwards 306A) where 15 nm of chromium and then 250 nm of high purity (99.9%) gold
were deposited at a rate of 0.1 nm/s and a pressure less than 7.5 x 10-7 Torr. After
removal from the evaporator, the gold chips were exposed (~30 s) to an ODT-saturated
PDMS stamp that had a 3-mm hole cut in its center. This inking procedure forms a
hydrophobic ring that defines the sample area to localize reagents as well as to minimize
sample and label consumption. The gold chips are then rinsed with ethanol and dried with
a high-purity stream of nitrogen.
Antibody Assay Protocol. The antibody assay protocol follows the procedure
optimized previously in our laboratory.27 The gold substrates were immersed in a 0.1 mM
ethanolic solution of DSP for ~8 h and then rinsed with ethanol and dried with high
purity nitrogen. Next, sheep-anti-human thrombin antibody was covalently immobilized
on the gold substrates by pipetting 20.0 µL of a 100 µg/mL solution onto the DSP-
modified domain of the capture substrate; the reaction proceeded for ~8 h. The substrates
were subsequently rinsed three times with 2 mL of 10 mM PBS. The next step placed
20.0 µL of SuperBlock blocking buffer onto the capture substrate for 12 h. The substrate
was again rinsed three times with 2 mL of 10 mM PBS. Once the capture substrate was
prepared in this manner, the thrombin (20.0 mL diluted in 10 mM PBS) was incubated
for ~8 h. The substrates were then rinsed with 2 mM borate buffer, 150 mM NaCl. The
labeling process (~12 h incubation) was performed by pipetting 20.0 µL of anti-human
thrombin ERLs onto the capture substrate. Finally, the substrates were rinsed with 2 mM
borate buffer, 150 mM NaCl, dried with high purity nitrogen, and the SERS spectra were
collected.
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Aptamer Assay Protocol. The unmodified center of the gold chips was exposed
to 20.0 µL of TBA (10 µM in 10 mM PBS) for ~12 h. These substrates were rinsed with
2 mL of 10 mM PBS and exposed to MHx for 1 h to orient TBA. Different
concentrations (100, 10, or 5 µM) of MHx were tested to find the optimal ratio of TBA to
MHx. The substrates were then rinsed with 10 mM PBS. The binding buffer composition
for extraction of thrombin was examined by diluting thrombin in 10 mM PBS containing
either 1.0 mM MgCl2 or 100 mM KCl. A sample volume of 20.0 µL was placed on the
capture surface and the thrombin was allowed to bind for ~8 h. The substrates were then
rinsed with 2 mM borate buffer (150 mM NaCl) and 20.0 µL of the ERLs were added
and allowed to bind for ~2 h. The substrates underwent a final rinse in 2 mM borate
buffer (150 mM NaCl), were dried with high purity nitrogen, and then interrogated by
SERS.
Instrumentation. Raman spectra were collected with a NanoRaman I
(Concurrent Analytical) fiber-optic Raman system. The excitation source is a 30-mW,
632.8 nm HeNe laser. The spectrograph consists of an f/2.0 Czerny-Turner imaging
spectrometer (resolution of 6-8 cm-1) and a thermoelectrically cooled CCD (Kodak
0401E). The probe objective focuses the laser to a 25-µm diameter spot on the substrate
surface; it also collects the scattered Raman radiation. All spectra were obtained with a 1-
s integration time.
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RESULTS AND DISCUSSION
Antibody Assay. As a starting point and a means to assess and contrast the
effectiveness of the antibody and aptamer assays, a sandwich immunoassay was
performed with sheep-anti-human thrombin used as the recognition element in both the
capture and labeling steps. These results are compared to those for an aptamer-based
assay as a means to contrast performance. Operationally, thrombin samples were
prepared by dilution in 10 mM PBS to varying concentrations and SERS spectra were
obtained for capture substrates exposed to each sample (Figure 1). The signal intensity of
these spectra, which contain features characteristic of the DSNB-based Raman reporter
molecule that confirm the presence of the ERLs, and exhibit an increase with the increase
in thrombin levels. The dominant feature in the spectra is the symmetric nitro stretch
[s(NO2)] at 1336 cm-1, which was used for quantification of thrombin.
The average intensity of s(NO2) from measurements collected at five different
locations on the sample was determined and plotted verses thrombin concentration
(Figure 2) to construct a dose-response curve. The error bars represent the standard
deviation in the signal. The horizontal line at 96 cts/s in Figure 2 represents the response
after addition of a signal that is three times the standard deviation of the blank; this
threshold is used to calculate the limit of detection (LOD). Based on these data, the
antibody sandwich assay for thrombin yields a limit of detection of 30 pM (2 x 10-3 NIH
units/mL), which is well below levels found in human plasma (5-500 NIH units/mL).28
Specificity of the capture substrate was examined by exposing the anti-thrombin
substrate to 1000 ng/mL of rabbit IgG, followed by labeling with ERLs prepared with
anti-rabbit IgG. This control study yielded SERS signals on par with the blank signal.
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TBA Immobilization Optimization. TBA was modified on the 3’ end with a six
carbon linker chain terminated at the distal end by a thiol group, which functions to
immobilize TBA to the gold substrate through a gold-thiolate linkage. Previous reports
have found that detection limits are compromised when TBA is immobilized to the
capture substrate via the 3’-end. This observation suggests that either 3’
modification/immobilization interferes with folding of the aptamer, or that 5’
modification/immobilization improves its ability to form the quadruplex structure.18
Additionally, surface bound TBA exhibits higher binding when a carbon spacer chain is
included, presumably due to the increased flexibility (reduced steric hindrance) of the
quadruplex structure.18 MHx is used as a co-absorber because its length matches that of
the six carbon linker chain on the TBA, and therefore should not interfere with TBA
folding or reactions with thrombin.29 MHx, a displacing molecule, orients the thiol
modified TBA along the surface normal to the substrate by reducing electrostatic
interactions between the DNA backbone and the gold surface.30 As a consequence, the
appropriate ratio of TBA and MHx must be determined in order to orient TBA, while
minimizing its displacement. Significant displacement of TBA would lower the amount
of TBA on the capture substrate, reducing the level of thrombin extracted from solution.31
Monolayers of TBA were constructed by exposure of the gold substrate to 10 µM
TBA for ~8 h. The TBA-adlayer was then partially displaced by three different
concentrations of MHx (5, 10, 100 µM) for 1 hr to overcome the electrostatic interactions
between the DNA and the gold surface. Thrombin was diluted to varying concentrations
in 10 mM PBS and then exposed to the capture substrate. Finally, antibody-coated ERLs
133
were exposed to the captured thrombin and SERS spectra were obtained. The intensity of
s(NO2) was used for quantification and the results are summarized in Figure 3.
A high concentration of MHx (100 µM) shows approximately the same, relatively
large, SERS signal for all concentrations of thrombin, including the blank. We speculate
that the highest concentration of MHx displaces a significant amount of TBA,31
producing a capture surface predominately coated with MHx, which appears to non-
specifically bind ERLs. Capture substrates prepared using the lowest concentration of
MHx, on the other hand, exhibit a much lower level of ERL binding at all thrombin
concentrations. We hypothesize in this case that only a small amount of the TBA has
been oriented properly to successfully extract thrombin (i.e., most of the TBA is
electrostatically attracted to the gold substrate through the DNA backbone and is
primarily oriented parallel to the surface).29, 31 Of these sets of tests, the optimal
concentration of MHx was found to be 10 µM, which is presumably a compromise
between reducing the non-specific interactions between ERLs and MHx, and more
favorably orienting the TBA for improved thrombin and subsequently ERL binding.
Binding Buffer Optimization. The importance of buffer composition was
examined by adding two different salts to the 10 mM PBS binding buffer, 100 mM KCl
or 1 mM MgCl2, and utilizing the optimized 10 µM MHx incubation. The cations of these
salts have been shown at these concentrations to shift the equilibrium of TBA from a
random conformation to the quadruplex conformation responsible for thrombin
binding.15, 16, 18, 19
Dose-response curves for thrombin in different binding buffers are depicted in
Figure 4, which shows that the SERS signals obtained for each binding buffer do not
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differ much from one another. The assay employing 1 mM MgCl2 as an additive to the
binding buffer exhibited the highest non-specific binding (i.e., blank signal of 343 ± 215
cts/s), yielding a LOD of 560 pM. The lowest blank signal (316 ± 99 cts/s) was obtained
using the 100 mM KCl binding buffer, but the responses were the least reproducible,
producing a LOD of 840 pM. The 10 mM PBS binding buffer had the most reproducible
responses and a low blank signal (453 ± 105 cts/s), yielding a limit of detection of 200
pM. Therefore, the addition of salt to the binding buffer did not improve the LOD,
suggesting that the cations do not have a strong impact on the stability of TBA with this
particular experimental design. We attribute this observation to two possible phenomena,
which may act alone or in concert. First, a few reports have indicated that cations only
facilitate quadruplex stability when near the TBA melting temperature (~46 ˚C). Our
experiments are performed at room temperature. Second, the TBA quadruplex formation
is induced by binding of thrombin, meaning the TBA folds upon association with
thrombin and thrombin becomes an integral part of the nucleic acid structure.13, 32 It was
concluded from these results that 10 mM PBS was the optimal binding buffer.
TBA Assay. Using the optimized conditions (i.e., 10 µM MHx and 10 mM PBS
binding buffer), an assay for thrombin was performed and compared to results from the
antibody assay (Figure 5). Both data sets exhibit the expected trend in SERS signal with
thrombin concentration. Interestingly, the SERS signal from the aptamer-based assay is
greater at all thrombin concentrations than that for the antibody-based assay. However,
the level of non-specific binding is more pronounced for the aptamer-based assay (blank
signal of 453 ± 105 cts/s), yielding a LOD of 200 pM (0.02 NIH units/mL).
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A control study for the aptamer-based assay exposed the TBA substrate to 1000
ng/mL of rabbit IgG, followed by labeling with ERLs prepared with anti-rabbit IgG. This
test of specificity yielded SERS signals that did not exceed those of the blank signal.
Although the signal intensity from the aptamer-based assay is larger than that of
the antibody-based assay, the LOD for the antibody-based assay was nearly seven times
lower at 30 pM. This difference largely reflects the smaller blank signal (72 ± 8 cts/s) in
the antibody-based assay.
Nonetheless, these results raise an important question: what is the orgin(s) of the
longer signal strengths in the aptamer-based assay? Potential answers to this question can
be developed by comparing the two sets of experiments. The higher SERS signals in the
aptamer-based assay could be attributed to a combination of three factors: 1) a higher
level of non-specific ERL binding due to ERL binding to the MHx spacer; 2) higher
surface concentration of the aptamer on the capture substrate due to its smaller size and
3) larger SERS enhancements because of a smaller separation between ERLs and the
gold substrate. Each of these possibilities are now examined in turn.
The first factor explaining the difference in signal intensities is that the aptamer
capture substrate has a higher level of non-specific binding due to interactions between
the MHx and ERLs. When, however, the blank response is subtracted from each trial, the
SERS signals from the aptamer-based assay are in all cases still greater than those from
the antibody assay. After background correction, the SERS signal is ~30% greater for the
aptamer assay at high thrombin concentrations (> 100 ng/mL), but is only ~5% greater at
low thrombin concentrations (<100 ng/mL). This observation suggests that other factors
are contributing to the signal differences in the two types of assays.
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A second explanation for the larger SERS signal for the aptamer assay rests with a
difference in the possible packing density of the recognition element for the two types of
capture substrates. That is, a TBA molecule is ~20 times smaller than an IgG antibody.
Assuming a 10nm diameter33 (area of 78 nm2), the surface concentration of a closest-
packed layer of antibodies is 2 x 10-12 mol/cm2. In contrast, the area occupied by TBA is
estimated based on the width of double stranded DNA (~2 nm) by the height of the TBA
structure (~3 nm).34 Using an area of 5 nm2 for TBA, the surface concentration is 3 x 10-
11 mol/cm2. If the MHx displaces half of the TBA (1:1 mixture), the surface concentration
of TBA would still be 10 times greater than that for the capture antibody.
Assuming all of the TBA and antibodies on the capture substrate are active, the
higher density of TBA would push the binding equilibrium to the TBA-thrombin
complex. At high concentrations of thrombin, then, more thrombin can be extracted, and
higher SERS signals can be achieved with the aptamer-based assay. For low
concentrations of thrombin, however, the differences in SERS signal might be less
pronounced because all thrombin may be extracted in both cases. The higher surface
concentration of TBA accounts for the higher SERS signals at high concentration, and
since the SERS signal after background correction for low thrombin concentrations is still
slightly larger for the aptamer capture, yet another factor must be considered.
The higher SERS signal for the aptamer assay may also be a consequence of a
larger SERS enhancement factor. This situation arises because the ERLs are closer to the
underlying gold substrate in the aptamer assay than in the antibody assay. A TBA adlayer
is ~2.6 nm high, while the antibody layer is as much as ~10 nm tall.33 It has been
demonstrated that the separation between an ERL and the underlying gold substrate has a
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profound effect on SERS enhancement.35-37 This dependence develops from the
sensitivity of the coupling between the surface plasmons of the gold cores of the ERLs
and the underlying gold of the capture substrate. 34 ERLs were found for our experimental
design, which utilizes a HeNe laser at 633 nm, to have a five-fold larger signal when
positioned closer to the underlying gold substrate (~1.2 nm vs ~2.3 nm).35 The ERLs
bound by aptamers should be closer than those at the capture antibody substrate, resulting
in larger signals at all thrombin concentrations.
We speculate that the high signals of the aptamer-based assay exhibited at higher
concentrations of thrombin are due to a combination of all three factors. That is, more
non-specific binding of the ERLs, more specific binding of thrombin due to the increased
surface concentration of TBA, and greater SERS enhancements because the ERLs are
closer to underlying substrate.
Low concentrations of thrombin, on the other hand, may only be experiencing
enhanced signals from two of the contributions: non-specific binding of ERLs, and gap
distance. The increased signal because of a higher surface concentration of TBA may not
have a significant impact at low thrombin concentrations, since in both the TBA-based
assay and the antibody-based assay all of the thrombin may be extracted. The small
signal increase of the TBA-based assay over the antibody-based assay (after background
correction) at low concentrations of thrombin, then, may be due solely to enhancements
from the smaller gap distance between the ERLs and the underlying substrate.
Finally, the blank (non-specific binding of ERLs) may be strongly influenced by
the ERLs being closer to the underlying substrate. If the same numbers of ERLs are non-
specifically bound in the aptamer- and antibody-based assays, the blank signal for the
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aptamer-based assay will be larger because those ERLs are closer to the gold substrate.
The higher background signal manifests itself into lower limits of detection for the
aptamer-based assay. As is the case with many sandwich immunoassays, the limit of
detection is controlled by non-specific binding.
Robustness of Capture Substrates. The antibody and aptamer capture substrates
were dried after preparation to test the robustness of both platforms. Substrates were
prepared following the optimized protocols, and then dried under a stream of high purity
nitrogen, and stored in a dessicator for 48 h. Results from tests of both the as-prepared
and the stored substrates compared to those prepared and used immediately are shown in
Figure 6. Both types of capture substrates show higher signals when dried and stored,
including higher blank signals.
The dried TBA substrates give a LOD of 2 nM compared to 0.2 nM for substrates
used immediately, a tenfold difference. The dried antibody substrate has a LOD of 500
pM, while those used without delay has a LOD of 32 pM. Drying the substrate has a
slightly larger impact on the antibody assay, with a 15-fold difference. This observation
is likely a result of the antibodies becoming irreversibly denatured when dried. Aptamers,
on the other hand, can reversibly undergo a change in structure. Nonetheless,
experiments to address the stability of these systems to facilitate long term storage are
being designed.
CONCLUSIONS
An aptamer based sandwich assay for thrombin detection using SERS as a readout
technique was developed and optimized. First, the immobilization procedure of the TBA
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to the gold substrate was optimized; the best conditions were found to be 10 µM TBA
incubation overnight followed by 10 µM MHx displacement for 1 h. Binding buffer
compositions were also studied and the optimal buffer was determined to be 10 mM PBS.
The limit of detection using antibodies is 30 pM (2 x 10-3 NIH units/mL) while the limit
of detection using aptamers is 200 pM (0.02 NIH units/mL). Both of theses limits of
detection are competitive with other methods for thrombin detection (112 pM for aptamer
beacons,19 1 nM for ELAA,18 and 3.5 nM with electrochemistry20) and are well within
the concentration range found in human plasma (5-500 NIH units/mL).
This paper shows the potential of aptamers as replacements for antibodies in a
SERS detection platform. The aptamer-based assay gives rise to higher analytical signals
at all thrombin concentrations (after background correction). These larger signals, if non-
specific binding can be reduced, offer a unique way of improving the limits of detection
that can be achieved using SERS as a readout technique. Methods to combat non-specific
binding are currently being investigated in our laboratory in order to fully exploit the
ultra-sensitive readout capabilities of SERS. SERS signals could be further increased by
preparing ERLs using aptamers as biorecognition moieties instead of antibodies, which
would place the ERLs even closer to the underlying substrate. Experiments to this end are
planned. Combining the sensitivity of SERS with the selectivity of aptamers presents an
opportunity to create analytical assays to detect low levels of pathogens or toxins.
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Scheme 1. Schematic representation of the aptamer assay platform. TBA is immobilized
on a gold substrate, followed by displacement of non-specifically bound TBA with MHx.
Thrombin is then extracted from solution and labeled with ERLs specific for thrombin.
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Figure 1. SERS spectra (1-s integration) for different concentrations of thrombin, diluted
in 10 mM PBS, in the antibody sandwich immunoassay.
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Figure 2. Dose-response curve for detection of thrombin in an antibody sandwich assay.
The solid line represents the blank signal plus three times its standard deviation.
146
Thrombin Concentration (ng/mL)
200 400 600 800 1000
SE
R
S
Si
gn
al
(ct
s/
s)
0
10000
20000
30000
40000
100 µM MHx
5 µM MHx
10 µM MHx
Figure 3. Dose-response curve for detection of thrombin in the aptamer/antibody
sandwich immunoassay at different MHx concentrations. The solid lines represent the
blank signal plus three times its standard deviation for each MHx concentration.
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Figure 4. Dose-response curve for detection of thrombin in the aptamer/antibody
sandwich immunoassay with different binding buffers. The solid lines represent the blank
signal plus three times its standard deviation for each binding buffer.
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Figure 5. Comparison of optimized assays for thrombin using a TBA or antibody capture
substrate. The solid lines represent the blank signal plus three times its standard
deviation.
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Figure 6. Dose-response curves for the detection of thrombin using A) antibody
substrates and B) aptamer substrates that were prepared and used immediately or dried
and stored for 48 h. Each solid line represents the blank signal plus three times its
standard deviation.
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GENERAL CONCLUSIONS
Research Overview
The main goal of this dissertation was to investigate several parameters that
dictate immunoassay performance. Chapter 1 began by investigating the assay conditions
required for detection of porcine parvovirus (PPV) and feline calicivirus (FCV) using
atomic force microscopy (AFM) as a readout method. Several antibodies for each virus
were screened to establish their effectiveness in a heterogeneous assay. The specificity of
the assay was examined, along with a method of converting the units of TCID50/mL to
number of virus particles/mL for FCV. A preliminary investigation of sample volume
considerations suggested that the use of large sample volumes would provide a simple
means for improving limits of detection. This concept was explored further in Chapter 3.
Limits of detection using the optimized conditions were 3.2 x 106 TCID50/mL for FCV,
and 6.4 x 104 TCID50/mL for PPV. The immunoassay procedures optimized in Chapter 1
were utilized in Chapters 2 and 3.
In an effort to extend the work of Chapter 1, Chapter 2 described a method of
improving mass transport of PPV and FCV to the capture substrate through the use of
elevated temperatures. Elevated temperatures can have many effects on the system
including: 1) an increase in the diffusion coefficient, 2) a change in the association and
dissociation rate constants between the reactants, and 3) an increase in analyte mass
transport due to thermally induced convection. The accumulation rates of PPV and FCV
were examined, both experimentally (by AFM) and theoretically, at different
temperatures. The accumulation of PPV followed the trend based upon the model, while
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curves for FCV deviated significantly from the predicted curve, presumably due to the
complex sample solution of the FCV. From this investigation, it was determined that
incubation times could be reduced from ~16 h to ~1 h with limits of detection being
reduced by less than a factor of 2. The findings of Chapter 2 emphasize the mass
transport limitations of many biosensing applications due to the small diffusion
coefficients of many biological elements.
Chapter 3 explored the manipulation of capture substrate area and sample volume
on the equilibrium concentration of bound PPV to understand the factors that contribute
to limits of detection. Surface-enhanced Raman scattering (SERS) was utilized as the
readout technique for this study due to its high sensitivity. The goal of this work was to
understand the achievable limits of detection for SERS readout. Theoretical
considerations revealed that in order to attain the highest surface concentration of antigen
at equilibrium, the volume of the antigen solution must be large enough to prevent
depletion. The experimental results show that the improvements in limits of detection can
be achieved by using small capture substrates and large volumes. A limit of detection of
750 aM was accomplished in this manner for PPV detection with SERS readout.
Finally, the use of aptamers as recognition elements for detection of thrombin was
investigated in Chapter 4. Aptamers have been shown to rival antibodies in their
sensitivity and specificity, and the merits of their use for SERS readout were investigated.
The conditions required for aptamer performance in a SERS-based detection platform
were optimized. Immobilization procedures and binding buffer composition were
examined and the results of the aptamer-based assay were compared and contrasted to
those from an antibody-based assay. Limits of detection for the aptamer-based and
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antibody-based platforms were 200 pM and 30 pM, respectively. Higher SERS signals
were obtained at all thrombin concentrations, including the blank, in the aptamer-based
platform. Since non-specific binding dictates the limit of detection, the antibody-based
assay yielded a better limit of detection.
Prospectus
The findings of this dissertation provide useful insights into the phenomena that
govern immunoassay performance. Chapter 1 detailed the effect of immobilization on
antibody activity for mAbs for PPV and FCV. Aptamers offer advantages over antibodies
in that they are less prone to denaturation, but the optimal experimental conditions must
be determined for each aptamer-based assay. The higher SERS signals observed in the
aptamer-based assay over the antibody-based assay for thrombin detection may provide
some insight into the mechanisms that govern SERS enhancements. The aptamer-based
assay places the ERLs closer to the underlying substrate, which may provide a means of
signal enhancement. A more detailed exploration into this observation would prove
useful for understanding the effect of gap distance between ERLs and the underlying gold
substrate on the SERS signal. The use of aptamers for both capture of the target and
labeling of the target (i.e., preparation of ERLs with aptamers as the biorecognition
moiety) would place the ERLs much closer to the underlying substrate than the analogous
antibody-based assay. Fixing of the antibody-based assay and the use of photo-aptamers
would allow rigorous rinsing of both substrates, and the number of ERLs bound for each
platform could be determined by AFM. The SERS signal for each ERL could then be
estimated to determine if larger SERS signals are obtained with a smaller gap distance.
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The results provided in Chapters 2 and 3 provide insights into the optimal
conditions for achieving the lowest levels of detection with immunoassay platforms.
First, long times are required to reach equilibrium for systems employing analytes with
large diffusion coefficients. The best limits of detection are achieved when equilibrium
has been established, as this condition yields the highest surface bound concentration of
analyte. Additionally, the equilibrium constant dictates the amount of analyte solution
required to prevent depletion, an ideal condition for achieving low limits of detection.
Even if the optimal conditions are employed to reach ultra-low levels of detection,
for most immunoassay platforms, the limit of detection is dictated by the amount of non-
specific binding. To capitalize on the sensitivity of SERS and AFM as readout methods
for immunoassays, non-specific binding must be reduced or eliminated. Insights into the
mechanisms that control non-specific binding would prove useful to improving limits of
detection for all sandwich-type immunoassays. If non-specific binding could be
eliminated, then ultra-low levels of detection could be reached by increasing the mass
transport and working in negligible depletion mode, which would allow the highest
surface bound concentration of analyte. Coupling these performance attributes with the
sensitivity of SERS and AFM, zeptomolar levels of detection could be within reach.
